<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:42:02Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7033872" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7033872</identifier>
        <datestamp>2020-02-27</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7033872</article-id>
              <article-id pub-id-type="pmcid">PMC7033872</article-id>
              <article-id pub-id-type="pmc-uid">7033872</article-id>
              <article-id pub-id-type="pmid">31986989</article-id>
              <article-id pub-id-type="pmid">31986989</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.119.014066</article-id>
              <article-id pub-id-type="publisher-id">JAH34769</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Interventional Cardiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction</article-title>
                <alt-title alt-title-type="left-running-head">Maznyczka etÂ al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah34769-cr-0001" contrib-type="author">
                  <name>
                    <surname>Maznyczka</surname>
                    <given-names>Annette M.</given-names>
                  </name>
                  <degrees>BSc(Hons), MBChB(Hons), MSc</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0002" contrib-type="author">
                  <name>
                    <surname>McCartney</surname>
                    <given-names>Peter J.</given-names>
                  </name>
                  <degrees>MBChB</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0003" contrib-type="author">
                  <name>
                    <surname>Oldroyd</surname>
                    <given-names>Keith G.</given-names>
                  </name>
                  <degrees>MD(Hons)</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0004" contrib-type="author">
                  <name>
                    <surname>Lindsay</surname>
                    <given-names>Mitchell</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0005" contrib-type="author">
                  <name>
                    <surname>McEntegart</surname>
                    <given-names>Margaret</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0006" contrib-type="author">
                  <name>
                    <surname>Eteiba</surname>
                    <given-names>Hany</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0007" contrib-type="author">
                  <name>
                    <surname>Rocchiccioli</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0008" contrib-type="author">
                  <name>
                    <surname>Good</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0009" contrib-type="author">
                  <name>
                    <surname>Shaukat</surname>
                    <given-names>Aadil</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0010" contrib-type="author">
                  <name>
                    <surname>Robertson</surname>
                    <given-names>Keith</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0011" contrib-type="author">
                  <name>
                    <surname>Kodoth</surname>
                    <given-names>Vivek</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0012" contrib-type="author">
                  <name>
                    <surname>Greenwood</surname>
                    <given-names>John P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0013" contrib-type="author">
                  <name>
                    <surname>Cotton</surname>
                    <given-names>James M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0014" contrib-type="author">
                  <name>
                    <surname>Hood</surname>
                    <given-names>Stuart</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0015" contrib-type="author">
                  <name>
                    <surname>Watkins</surname>
                    <given-names>Stuart</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0016" contrib-type="author">
                  <name>
                    <surname>Macfarlane</surname>
                    <given-names>Peter W.</given-names>
                  </name>
                  <degrees>DSc</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0017" contrib-type="author">
                  <name>
                    <surname>Kennedy</surname>
                    <given-names>Julie</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0018" contrib-type="author">
                  <name>
                    <surname>Tait</surname>
                    <given-names>R. Campbell</given-names>
                  </name>
                  <degrees>MBChB</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0019" contrib-type="author">
                  <name>
                    <surname>Welsh</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0020" contrib-type="author">
                  <name>
                    <surname>Sattar</surname>
                    <given-names>Naveed</given-names>
                  </name>
                  <degrees>FMedSci</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0021" contrib-type="author">
                  <name>
                    <surname>Collison</surname>
                    <given-names>Damien</given-names>
                  </name>
                  <degrees>MBChB</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0022" contrib-type="author">
                  <name>
                    <surname>Gillespie</surname>
                    <given-names>Lynsey</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0023" contrib-type="author">
                  <name>
                    <surname>McConnachie</surname>
                    <given-names>Alex</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah34769-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah34769-cr-0024" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Berry</surname>
                    <given-names>Colin</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah34769-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>colin.berry@glasgow.ac.uk</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah34769-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">British Heart Foundation Glasgow Cardiovascular Research Centre</named-content>
                <named-content content-type="organisation-division">Institute of Cardiovascular and Medical Sciences</named-content>
                <institution>University of Glasgow</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">West of Scotland Heart and Lung Centre</named-content>
                <institution>Golden Jubilee National Hospital, Clydebank</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Leeds University and Leeds Teaching Hospitals NHS Trust</institution>
                <city>Leeds</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Wolverhampton University Hospital NHS Trust</institution>
                <city>Wolverhampton</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Electrocardiology Group</institution>
                <institution>Royal Infirmary</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Haematology</named-content>
                <institution>Royal Infirmary</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Project Management Unit</named-content>
                <institution>Greater Glasgow and Clyde Health Board</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah34769-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Robertson Centre for Biostatistics</named-content>
                <institution>Institute of Health and Wellbeing, University of Glasgow</institution>
                <city>Glasgow</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Colin Berry, PhD, British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Place, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom. Eâmail: <email>colin.berry@glasgow.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>1</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>04</day>
                <month>2</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>3</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.3</issue-id>
              <elocation-id>e014066</elocation-id>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>8</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>12</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>-->
                <copyright-statement content-type="article-copyright">Â© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license license-type="creativeCommonsBy">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e014066.pdf"/>
              <abstract id="jah34769-abs-0001">
                <sec id="jah34769-sec-0001">
                  <title>Background</title>
                  <p>Impaired microcirculatory reperfusion worsens prognosis following acute <styled-content style="fixed-case" toggle="no">ST</styled-content>âsegmentâelevation myocardial infarction. In the Tâ<styled-content style="fixed-case" toggle="no">TIME</styled-content> (A Trial of LowâDose Adjunctive Alteplase During Primary PCI) trial, microvascular obstruction on cardiovascular magnetic resonance imaging did not differ with adjunctive, lowâdose, intracoronary alteplase (10 or 20Â mg) versus placebo during primary percutaneous coronary intervention. We evaluated the effects of intracoronary alteplase, during primary percutaneous coronary intervention, on the index of microcirculatory resistance, coronary flow reserve, and resistive reserve ratio.</p>
                </sec>
                <sec id="jah34769-sec-0002">
                  <title>Methods and Results</title>
                  <p>A prespecified physiology substudy of the Tâ<styled-content style="fixed-case" toggle="no">TIME</styled-content> trial. From 2016 to 2017, patients with <styled-content style="fixed-case" toggle="no">ST</styled-content>âsegmentâelevation myocardial infarction â¤6Â hours from symptom onset were randomized in a doubleâblind study to receive alteplase 20Â mg, alteplase 10Â mg, or placebo infused into the culprit artery postreperfusion, but prestenting. Index of microcirculatory resistance, coronary flow reserve, and resistive reserve ratio were measured after percutaneous coronary intervention. Cardiovascular magnetic resonance was performed at 2 to 7Â days and 3 months. Analyses in relation to ischemic time (&lt;2, 2â4, and â¥4Â hours) were prespecified. One hundred fortyâfour patients (mean age, 59Â±11Â years; 80% male) were prospectively enrolled, representing 33% of the overall population (n=440). Overall, index of microcirculatory resistance (median, 29.5; interquartile range, 17.0â55.0), coronary flow reserve(1.4 [1.1â2.0]), and resistive reserve ratio (1.7 [1.3â2.3]) at the end of percutaneous coronary intervention did not differ between treatment groups. Interactions were observed between ischemic time and alteplase for coronary flow reserve (<italic>P</italic>=0.013), resistive reserve ratio (<italic>P</italic>=0.026), and microvascular obstruction (<italic>P</italic>=0.022), but not index of microcirculatory resistance.</p>
                </sec>
                <sec id="jah34769-sec-0003">
                  <title>Conclusions</title>
                  <p>In <styled-content style="fixed-case" toggle="no">ST</styled-content>âsegmentâelevation myocardial infarction with ischemic time â¤6Â hours, there was overall no difference in microvascular function with alteplase versus placebo.</p>
                </sec>
                <sec id="jah34769-sec-0004">
                  <title>Clinical Trial Registration</title>
                  <p><styled-content style="fixed-case" toggle="no">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case" toggle="no">NCT</styled-content>02257294.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah34769-kwd-0001">cardiovascular magnetic resonance</kwd>
                <kwd id="jah34769-kwd-0002">fibrinolysis</kwd>
                <kwd id="jah34769-kwd-0003">microvascular obstruction</kwd>
                <kwd id="jah34769-kwd-0004">primary PCI</kwd>
                <kwd id="jah34769-kwd-0005">STâsegmentâelevation myocardial infarction</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Myocardial Infarction</kwd>
                <kwd>Percutaneous Coronary Intervention</kwd>
                <kwd>Treatment</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>British Heart Foundation </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000274</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>FS/16/74/32573</award-id>
                  <award-id>RE/18/6/34217</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>National Institute for Health Research NIHRâEME</funding-source>
                  <award-id>12/170/4</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="5"/>
                <page-count count="33"/>
                <word-count count="10467"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>04 February 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.5 mode:remove_FC converted:04.02.2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah34769-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>e014066</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.119.014066</pub-id>.)<pub-id pub-id-type="pmid">31986989</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body id="jah34769-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="jah34769-blkfxd-0001" orientation="portrait">
                <sec id="jah34769-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah34769-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah34769-list-0001">
                        <list-item>
                          <p>Overall, there was no difference in index of microcirculatory resistance, coronary flow reserve, or resistive reserve ratio with alteplase versus placebo.</p>
                        </list-item>
                        <list-item>
                          <p>Patients presenting with a limited ischemic time (&lt;2Â hours) had doseârelated improvements in microvascular function (coronary flow reserve and resistive reserve ratio) with alteplase versus placebo.</p>
                        </list-item>
                        <list-item>
                          <p>Patients presenting with longer ischemic times (â¥4Â hours) had increased microvascular obstruction extent with alteplase versus placebo.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah34769-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah34769-list-0002">
                        <list-item>
                          <p>The findings are relevant to ongoing trials of intracoronary fibrinolytics during primary percutaneous coronary intervention, and to clinicians considering bailâout lytic therapy in acute STâsegmentâelevation myocardial infarction patients, with high thrombus burden and no reflow.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec id="jah34769-sec-0009">
              <title>Introduction</title>
              <p>Failed myocardial reperfusion affects approximately half of patients with acute STâsegmentâelevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI)<xref rid="jah34769-bib-0001" ref-type="ref">1</xref> and microvascular obstruction confers a worse prognosis.<xref rid="jah34769-bib-0002" ref-type="ref">2</xref>, <xref rid="jah34769-bib-0003" ref-type="ref">3</xref>, <xref rid="jah34769-bib-0004" ref-type="ref">4</xref> Microvascular obstruction is an acute, but potentially reversible, pathology. The pathophysiology includes microvascular thrombi, endothelial disruption, and, if reperfusion does not occur, then irreversible hemorrhagic transformation occurs within the infarct core.<xref rid="jah34769-bib-0005" ref-type="ref">5</xref>
</p>
              <p>Facilitated PCI with fullâ or halfâdose fibrinolytic therapy given intravenously preâPCI improves initial coronary flow, but promotes paradoxical thrombus formation, which counteracts fibrinolysis and is associated with higher residual thrombus burden, thrombotic complications, bleeding, and mortality.<xref rid="jah34769-bib-0006" ref-type="ref">6</xref>, <xref rid="jah34769-bib-0007" ref-type="ref">7</xref>, <xref rid="jah34769-bib-0008" ref-type="ref">8</xref> In the TâTIME (A Trial of LowâDose Adjunctive Alteplase During Primary PCI) trial (NCT02257294), we hypothesized that lowâdose, intracoronary fibrinolysis with adequate anticoagulation would reduce intracoronary and microvascular thrombosis and distal embolization without activating thrombus formation, thereby reducing microvascular obstruction. However, as assessed by contrastâenhanced cardiovascular magnetic resonance (CMR) imaging, microvascular obstruction did not differ with lowâdose intracoronary alteplase versus placebo.<xref rid="jah34769-bib-0009" ref-type="ref">9</xref>
</p>
              <p>In contrast with CMR, the index of microcirculatory resistance (IMR) quantifies immediate efficacy of microcirculatory reperfusion.<xref rid="jah34769-bib-0010" ref-type="ref">10</xref>, <xref rid="jah34769-bib-0011" ref-type="ref">11</xref> Elevated IMR is quantitatively associated with microvascular obstruction,<xref rid="jah34769-bib-0012" ref-type="ref">12</xref>, <xref rid="jah34769-bib-0013" ref-type="ref">13</xref> myocardial hemorrhage,<xref rid="jah34769-bib-0012" ref-type="ref">12</xref> worse recovery of infarct size,<xref rid="jah34769-bib-0014" ref-type="ref">14</xref> and adverse left ventricular (LV) remodeling and function.<xref rid="jah34769-bib-0015" ref-type="ref">15</xref> In acute STEMI, an IMR â¤32 postâPCI predicts recovery of LV function<xref rid="jah34769-bib-0016" ref-type="ref">16</xref> whereas an IMR â¥32 predicts allâcause death or rehospitalization for heart failure.<xref rid="jah34769-bib-0013" ref-type="ref">13</xref> An IMR &gt;40 after primary PCI has been associated with allâcause death, heart failure readmissions, and major adverse cardiac events.<xref rid="jah34769-bib-0013" ref-type="ref">13</xref>, <xref rid="jah34769-bib-0014" ref-type="ref">14</xref>, <xref rid="jah34769-bib-0015" ref-type="ref">15</xref>
</p>
              <p>Resistive reserve ratio (RRR) measures the vasodilatory capacity of the coronary microcirculation. It is the ratio between basal resting tone and resistance at maximal hyperemia and is lower when microvasodilatation is impaired. Coronary flow reserve (CFR) reflects epicardial and microcirculatory vasodilator capacity, as well as residual epicardial stenosis. CFR is the ratio of hyperemic to resting coronary blood flow. In acute STEMI, a lower RRR and CFR predict microvascular obstruction<xref rid="jah34769-bib-0012" ref-type="ref">12</xref>, <xref rid="jah34769-bib-0017" ref-type="ref">17</xref> and larger infarction.<xref rid="jah34769-bib-0017" ref-type="ref">17</xref>, <xref rid="jah34769-bib-0018" ref-type="ref">18</xref>
</p>
              <p>We prospectively investigated the effects of intracoronary alteplase during primary PCI on acute invasive parameters of microcirculatory function. We hypothesized that intracoronary alteplase would be associated with lower IMR, higher CFR, and higher RRR. Second, we hypothesized that the effects of alteplase on IMR, CFR, and RRR may vary with ischemic time, TIMI (Thrombolysis in Myocardial Infarction) thrombus grade, and TIMI coronary flow grade at the time of drug delivery (prespecified interaction analyses).</p>
            </sec>
            <sec id="jah34769-sec-0010">
              <title>Methods</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
              <sec id="jah34769-sec-0011">
                <title>Study Design and Patient Selection</title>
                <p>We performed a predefined, prospective, nested substudy within the main TâTIME trial. From August 2016 to December 2017, patients with acute STEMI from 3 hospitals in the United Kingdom were randomized in a 1:1:1 doseâranging, doubleâblind study. The protocol is summarized in FigureÂ <xref rid="jah34769-fig-0001" ref-type="fig">1</xref>. Participants were treated according to contemporary practice guideline recommendations.<xref rid="jah34769-bib-0004" ref-type="ref">4</xref>
</p>
                <fig fig-type="Figure" xml:lang="en" id="jah34769-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Illustration of the study design. Acute <styled-content style="fixed-case" toggle="no">STEMI</styled-content> patients meeting the eligibility criteria were enrolled in the catheterization laboratory and randomized to placebo, alteplase 10Â mg, or alteplase 20Â mg, in a 1:1:1 doseâranging, doubleâblind design. <styled-content style="fixed-case" toggle="no">CFR</styled-content> indicates coronary flow reserve; <styled-content style="fixed-case" toggle="no">IMH</styled-content>, intramyocardial hemorrhage; <styled-content style="fixed-case" toggle="no">IMR</styled-content>, index of microcirculatory resistance; <styled-content style="fixed-case" toggle="no">MVO</styled-content>, microvascular obstruction; PCI, percutaneous coronary intervention; <styled-content style="fixed-case" toggle="no">RRR</styled-content>, resistive reserve ratio; STEMI, STâsegmentâelevation myocardial infarction.</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e014066-g001"/>
                </fig>
                <p>Patients were eligible for study participation if they presented with persistent STâsegment elevation or recent left bundle branch block within 6Â hours of symptom onset and either an occluded culprit artery (TIMI coronary flow grade â¤1) or reduced flow (TIMI flow grade 2, slow but complete filling) in the presence of angiographic evidence of thrombus (TIMI thrombus grade â¥2). Eligibility required radial artery access, and the occlusion had to be in the proximal or mid segment of a major coronary artery. Exclusion criteria included a functional coronary collateral supply (Rentrop grade â¥2) to the culprit artery, cardiogenic shock, comorbidities with expected survival &lt;1Â year and contraindications to fibrinolysis, or CMR. The full list of eligibility criteria is provided in Data <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
                <p>Enrollment into the physiology study within the 3 designated sites was based on prospective assessment of eligibility criteria, operator experience, and logistical considerations at the point of care. A screening register was prospectively completed to document the reasons for participation or not. Witnessed verbal assent to participate in the study was obtained in the catheterization laboratory, and written informed consent was subsequently obtained on the ward. The study complied with the Declaration of Helsinki<xref rid="jah34769-bib-0019" ref-type="ref">19</xref> and was approved by the West of Scotland Research Ethics Committee (reference 13âWSâ0119).</p>
              </sec>
              <sec id="jah34769-sec-0012">
                <title>Randomization and Intervention</title>
                <p>Patients were randomized using an interactive voiceâresponseâbased system. The randomization sequence was computer generated, using the method of randomized permuted blocks of length 6, with stratification by location of STEMI (anterior versus nonanterior). The allocation sequence was on a 1:1:1 basis between placebo and the reduced dose alteplase groups (10, 20Â mg; ie, oneâtenth or oneâfifth of the standard dose). Patients, staff, and researchers were blinded to treatment group allocation.</p>
                <p>After successful reperfusion (TIMI flow grade â¥2) was achieved, using balloon angioplasty and/or aspiration thrombectomy, patients received the allocated intervention immediately in the catheterization laboratory. The 20âmL volume of study drug was manually infused into the culprit coronary artery over 5 to 10Â minutes proximal to the culprit lesion, using either an intracoronary catheter or the guiding catheter if selectively engaged.</p>
              </sec>
              <sec id="jah34769-sec-0013">
                <title>Intracoronary Physiology Measurements and Analysis</title>
                <p>IMR, CFR, and RRR were measured at the end of primary PCI, using a pressureâ and temperatureâsensing guidewire (Abbott Vascular, Santa Clara, CA). All patients received 200Â Î¼g of intracoronary nitroglycerin in the culprit artery. The calibrated wire was equalized to guide catheter pressure, then advanced to the distal third of the culprit artery. Using standard thermodilution methodology, mean transit time (Tmn) of a handâinjected 3âmL bolus of roomâtemperature saline was measured in triplicate at rest and during steadyâstate maximal hyperemia induced by intravenous adenosine (140Â Î¼g/kg/min). In order to mitigate the possibility of bias through disclosure of the IMR, CFR, and RRR results, the operators were blinded. The blinding process involved obscuring the display of the RadiAnalyzer Xpress monitor by turning it away from the clinician and other clinical staff. Experienced physiology technicians recorded the thermodilution data and quality assured the acquisition.</p>
                <p>IMR was quantified by distal coronary pressure Ã Tmn during hyperemia.<xref rid="jah34769-bib-0020" ref-type="ref">20</xref> At the end of primary PCI when IMR was measured after stenting, there was no residual epicardial stenosis, and therefore IMR correction with coronary wedge pressure<xref rid="jah34769-bib-0021" ref-type="ref">21</xref> or Yong's formula<xref rid="jah34769-bib-0022" ref-type="ref">22</xref> was not required. CFR was quantified by dividing resting Tmn by hyperemic Tmn.<xref rid="jah34769-bib-0023" ref-type="ref">23</xref>, <xref rid="jah34769-bib-0024" ref-type="ref">24</xref> RRR was quantified by dividing the baseline resistance index (distal coronary pressure Ã Tmn under resting conditions) by IMR.<xref rid="jah34769-bib-0025" ref-type="ref">25</xref> The shape of the hyperemic thermodilution curves was assessed as narrow unimodal, wide unimodal, or bimodal.<xref rid="jah34769-bib-0026" ref-type="ref">26</xref> A narrow unimodal waveform was defined as an acute temperature reduction (duration of &lt;0.42Â seconds from the beginning of the temperature reduction to nadir temperature), followed by rapid return to resting temperature. A wide unimodal waveform was defined as a temperature decrease to nadir &gt;0.42Â seconds, followed by a gradual return to baseline temperature. A bimodal waveform was defined as having 2 distinct nadirs, with a valley deeper than 20% of peak temperature drop.</p>
                <p>All data were extracted from the RadiAnalyzer Xpress instrument and then analyzed offline using Coroflow software (Coroventis Research AB, Uppsala, Sweden) by an investigator blinded to treatment allocation and blinded to CMR data. The coronary physiology data were subject to a second read, and final data were established by consensus agreement.</p>
              </sec>
              <sec id="jah34769-sec-0014">
                <title>Angiographic, ECG, and Troponin Analyses</title>
                <p>ECG and angiographic end points were determined by blinded core laboratory analysis, using standard operating procedures.</p>
                <p>Angiograms were analyzed by A.M.M. and then subject to a second read by 1 of 2 interventional cardiologists, both with &gt;10Â years of experience. Discrepancies were resolved by consensus agreement between the first and second reviewers, or where discrepancies remained consensus was reached after discussion with a third reviewer. The following were assessed in the culprit artery: TIMI coronary flow grade, TIMI frame count, myocardial perfusion grade, and TIMI thrombus grade. The angiogram acquisition protocol required stored fluoroscopy of study drug administration to enable verification by the core laboratory that the guide catheter was selectively engaged in the culprit artery when used to deliver study drug. Angiographic methods are described in detail in Data <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
                <p>The absolute percentage STâsegment resolution on ECGs obtained 60Â minutes after reperfusion compared with prereperfusion was calculated. Troponin T area under the curve was measured from blood samples obtained immediately prereperfusion (0Â hours) and then again 2Â  and 24Â hours later.</p>
              </sec>
              <sec id="jah34769-sec-0015">
                <title>Cardiovascular Magnetic Resonance</title>
                <p>CMR imaging was performed at 1.5 Tesla. The standard operating procedure for CMR included: (1) microvascular obstruction presence and extent (% LV mass) demonstrated by late gadolinium enhancement images; (2) myocardial hemorrhage presence and extent (% LV mass) demonstrated by T<sub>2</sub>* mapped images; (3) infarct size (% LV mass) demonstrated by late gadolinium enhancement images; and (4) LV ejection fraction. Microvascular obstruction and myocardial hemorrhage were reported 2 to 7Â days postâSTEMI; the other CMR parameters were reported at 2 to 7Â days and 3Â months postâSTEMI. A detailed description of the CMR acquisition and analysis techniques are in Data <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S1</xref>.</p>
              </sec>
              <sec id="jah34769-sec-0016">
                <title>Coagulation</title>
                <p>Coagulation and hemostasis parameters were measured in peripheral blood samples taken prereperfusion, then 2 and 24Â hours postreperfusion. The parameters included fibrinogen and plasminogen (measures of systemic fibrinolysis), fibrin Dâdimer (a measure of fibrin lysis), tissue plasminogen activator (a measure of endogenous fibrinolytic system activation and circulating alteplase), and prothrombin fragment F<sub>1+2</sub> (a measure of thrombin activation).</p>
              </sec>
              <sec id="jah34769-sec-0017">
                <title>Clinical Outcomes</title>
                <p>Clinical outcomes were prospectively collected between the index event and 3âmonth followâup. Major adverse cardiac events was defined as cardiovascular death, nonfatal myocardial infarction, or unplanned hospitalization for heart failure. Allâcause death and heart failure hospitalization were also reported. All events were adjudicated by a clinical event committee who were independent of the trial and blinded to the treatment allocation.</p>
              </sec>
              <sec id="jah34769-sec-0018">
                <title>Sample Size</title>
                <p>Sampleâsize calculation was based on data from the MRâMI (Magnetic Resonance Imaging in Acute STâSegment Elevation Myocardial Infarction) cohort study<xref rid="jah34769-bib-0012" ref-type="ref">12</xref>, <xref rid="jah34769-bib-0015" ref-type="ref">15</xref> in patients who fulfilled the eligibility criteria for TâTIME. For a comparison of IMR between 3 groups (placebo versus alteplase 10Â mg versus alteplase 20Â mg), assuming a mean IMR of 33.9 and an SD of 25.2, and assuming mean differences in IMR between the 10 and 20Â mg alteplase groups versus placebo of 10 and 20, respectively, then 108 subjects (36/group) were needed for 85% power and a significance level of 0.05. For a comparison of CFR between 3 groups (placebo versus alteplase 10Â mg versus alteplase 20Â mg), assuming a mean CFR of 1.65 and an SD of 0.8, and assuming mean differences in CFR between the 10 and 20Â mg alteplase groups versus placebo were 0.4 and 0.8, respectively, then 69 subjects (n=23/group) were needed with 85% power (Î±=0.05).</p>
              </sec>
              <sec id="jah34769-sec-0019">
                <title>Statistical Analysis</title>
                <p>Analyses were performed according to treatment received (alteplase 10 mg, 20Â mg, or placebo). Primary and secondary outcomes were assessed using linear regression (continuousÂ outcomes), logistic regression (binary outcomes), or proportional odds logistic regression (ordinal outcomes) to make treatment effect estimates. In linear regression models, logarithmic or square root transformations were used, where necessary, to improve model residual distributions. We performed post hoc analyses in prespecified subgroups. We prespecified subgroups of interest according to patient characteristics: (1) ischemic time (&lt;2, 2â4, and â¥4Â hours); (2) TIMI thrombus grade immediately prestudy drug (â¤2 and â¥3); and (3) TIMI coronary flow grade immediately prestudy drug (â¤2, and 3). These subgroups were based on an a priori concern that they were clinically relevant patient characteristics that could potentially impact on associations of alteplase with IMR, CFR, and RRR. Regression models were used to assess treatment effects within prespecified subgroups through use of treatmentâbyâsubgroup interactions. Interaction test <italic>P</italic> values, reported from regression models, included treatment group as a 3âlevel categorical variable or as a 2âlevel categorical variable (active versus placebo) and treatment modeled as a linear trend across dose groups (0, 10, and 20Â mg). Regression analyses were adjusted for location of the myocardial infarction. All tests were 2âtailed and assessed at the 5% significance level. There was no imputation for missing values, and no adjustments for multiple statistical comparisons were made. Data were analyzed using R software (R Development Core Team, Los Angeles, CA), according to a statistical analysis plan that was finalized before data lock.</p>
              </sec>
            </sec>
            <sec id="jah34769-sec-0020">
              <title>Results</title>
              <sec id="jah34769-sec-0021">
                <title>Study Population Characteristics</title>
                <p>Participantsâ characteristics are shown in TablesÂ <xref rid="jah34769-tbl-0001" ref-type="table">1</xref> and <xref rid="jah34769-tbl-0002" ref-type="table">2</xref>. The flow of subjects through the study is summarized in FigureÂ <xref rid="jah34769-fig-0002" ref-type="fig">2</xref>. The sample size (n=144) represented 33% of the overall study population, and their characteristics were broadly similar. Mean age was 59.4Â±10.5Â years, and 80% were male. Median ischemic time was 2.5Â hours (interquartile range [IQR], 2.0, 3.5), and 31 (22%) had an ischemic time &lt;2Â hours. The culprit coronary artery was the left anterior descending in 38% (n=54), circumflex in 17% (n=24), and right in 46% (n=66) of patients.</p>
                <table-wrap id="jah34769-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Population Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">All [n=144]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Placebo [n=53]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Alteplase 10Â mg [n=41]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Alteplase 20Â mg [n=50]</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Demographics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">59.4Â±10.5</td>
                        <td align="left" rowspan="1" colspan="1">56.8Â±11.3</td>
                        <td align="left" rowspan="1" colspan="1">61.2Â±9.4</td>
                        <td align="left" rowspan="1" colspan="1">60.6Â±10.3</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">115 (80%)</td>
                        <td align="left" rowspan="1" colspan="1">45 (85%)</td>
                        <td align="left" rowspan="1" colspan="1">31 (76%)</td>
                        <td align="left" rowspan="1" colspan="1">39 (78%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">28.4Â±5.1</td>
                        <td align="left" rowspan="1" colspan="1">28.8Â±5.3</td>
                        <td align="left" rowspan="1" colspan="1">29.0Â±5.2</td>
                        <td align="left" rowspan="1" colspan="1">27.4Â±4.6</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ischemic time, h:mm median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">2:47 (2:03, 3:50)</td>
                        <td align="left" rowspan="1" colspan="1">2:40 (2:03, 3:52)</td>
                        <td align="left" rowspan="1" colspan="1">2:43 (1:53, 4:10)</td>
                        <td align="left" rowspan="1" colspan="1">2:54 (2:10, 3:36)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Medical history</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">41 (28%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (26%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">16 (32%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypercholesterolemia</td>
                        <td align="left" rowspan="1" colspan="1">21 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (21%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus<xref ref-type="fn" rid="jah34769-note-0003">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">16 (11%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (11%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Smoking</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Current</td>
                        <td align="left" rowspan="1" colspan="1">68 (47%)</td>
                        <td align="left" rowspan="1" colspan="1">25 (47%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (41%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (52%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Former</td>
                        <td align="left" rowspan="1" colspan="1">27 (19%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (25%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (14%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Never</td>
                        <td align="left" rowspan="1" colspan="1">49 (34%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (28%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (41%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (34%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous PCI</td>
                        <td align="left" rowspan="1" colspan="1">9 (6%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (6%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous MI</td>
                        <td align="left" rowspan="1" colspan="1">8 (6%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angina</td>
                        <td align="left" rowspan="1" colspan="1">4 (3%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke/TIA</td>
                        <td align="left" rowspan="1" colspan="1">3 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Preâexisting maintenance medication</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                        <td align="left" rowspan="1" colspan="1">20 (14%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (16%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">P2Y<sub>12</sub> inhibitor</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clopidogrel</td>
                        <td align="left" rowspan="1" colspan="1">1 (1%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ticagrelor/prasugrel</td>
                        <td align="left" rowspan="1" colspan="1">2 (1%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                        <td align="left" rowspan="1" colspan="1">25 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (25%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Îetaâblocker</td>
                        <td align="left" rowspan="1" colspan="1">14 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACEi or ARB</td>
                        <td align="left" rowspan="1" colspan="1">18 (12%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (13%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (14%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">MRA</td>
                        <td align="left" rowspan="1" colspan="1">3 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (5%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Hemodynamic measures and initial blood results on admission</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart rate, bpm</td>
                        <td align="left" rowspan="1" colspan="1">73.0Â±15.1</td>
                        <td align="left" rowspan="1" colspan="1">74.4Â±16.1</td>
                        <td align="left" rowspan="1" colspan="1">71.5Â±13.0</td>
                        <td align="left" rowspan="1" colspan="1">72.7Â±15.8</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">140Â±26</td>
                        <td align="left" rowspan="1" colspan="1">140Â±28</td>
                        <td align="left" rowspan="1" colspan="1">141Â±23</td>
                        <td align="left" rowspan="1" colspan="1">138Â±27</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic BP, mmÂ Hg</td>
                        <td align="left" rowspan="1" colspan="1">82Â±15</td>
                        <td align="left" rowspan="1" colspan="1">84Â±17</td>
                        <td align="left" rowspan="1" colspan="1">82Â±13</td>
                        <td align="left" rowspan="1" colspan="1">81Â±16</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine, Î¼mol/L<xref ref-type="fn" rid="jah34769-note-0004">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">79Â±16</td>
                        <td align="left" rowspan="1" colspan="1">79Â±16</td>
                        <td align="left" rowspan="1" colspan="1">80Â±14</td>
                        <td align="left" rowspan="1" colspan="1">79Â±17</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">eGFR, mL/min/1.73Â m<sup>2</sup>
<xref ref-type="fn" rid="jah34769-note-0004">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">91Â±21</td>
                        <td align="left" rowspan="1" colspan="1">94Â±22</td>
                        <td align="left" rowspan="1" colspan="1">88Â±18</td>
                        <td align="left" rowspan="1" colspan="1">92Â±22</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin, g/L<xref ref-type="fn" rid="jah34769-note-0004">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">145.8Â±13.7</td>
                        <td align="left" rowspan="1" colspan="1">145.4Â±13.8</td>
                        <td align="left" rowspan="1" colspan="1">146.2Â±12.6</td>
                        <td align="left" rowspan="1" colspan="1">146.0Â±14.6</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet count, 10<sup>9</sup>/L<xref ref-type="fn" rid="jah34769-note-0004">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">264.2Â±62.1</td>
                        <td align="left" rowspan="1" colspan="1">252.4Â±53.6</td>
                        <td align="left" rowspan="1" colspan="1">280.9Â±73.5</td>
                        <td align="left" rowspan="1" colspan="1">262.9Â±58.1</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34769-ntgp-0002">
                    <fn id="jah34769-note-0002">
                      <p>Data are meanÂ±SD, or n (%), unless otherwise stated. ACEi indicates angiotensinâconverting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.</p>
                    </fn>
                    <fn id="jah34769-note-0003">
                      <label>a</label>
                      <p>Diabetes mellitus was defined as a history of dietâcontrolled or treated diabetes mellitus.</p>
                    </fn>
                    <fn id="jah34769-note-0004">
                      <label>b</label>
                      <p>Missing data: creatinine, eGFR, hemoglobin, and platelets, 1 subject (alteplase 20Â mg group).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="jah34769-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Procedure Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">All [n=144]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Placebo [n=53]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Alteplase 10Â mg [n=41]</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Alteplase 20Â mg [n=50]</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Culprit artery</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LAD</td>
                        <td align="left" rowspan="1" colspan="1">54 (38%)</td>
                        <td align="left" rowspan="1" colspan="1">19 (36%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (41%)</td>
                        <td align="left" rowspan="1" colspan="1">18 (36%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Circumflex</td>
                        <td align="left" rowspan="1" colspan="1">24 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (22%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">RCA</td>
                        <td align="left" rowspan="1" colspan="1">66 (46%)</td>
                        <td align="left" rowspan="1" colspan="1">25 (47%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (37%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (52%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Culprit artery diameter, mm</td>
                        <td align="left" rowspan="1" colspan="1">3.2 Â±0.4</td>
                        <td align="left" rowspan="1" colspan="1">3.2Â±0.5</td>
                        <td align="left" rowspan="1" colspan="1">3.2Â±0.5</td>
                        <td align="left" rowspan="1" colspan="1">3.2Â±0.4</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Balloon angioplasty prestent</td>
                        <td align="left" rowspan="1" colspan="1">141 (98%)</td>
                        <td align="left" rowspan="1" colspan="1">51 (96%)</td>
                        <td align="left" rowspan="1" colspan="1">41 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">49 (98%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Initial angiography</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">TIMI coronary flow grade</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">114 (79%)</td>
                        <td align="left" rowspan="1" colspan="1">47 (89%)</td>
                        <td align="left" rowspan="1" colspan="1">34 (83%)</td>
                        <td align="left" rowspan="1" colspan="1">33 (66%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">14 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (7%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (18%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">16 (11%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (16%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">TIMI thrombus grade</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (6%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">25 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (11%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (12%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (28%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">116 (81%)</td>
                        <td align="left" rowspan="1" colspan="1">47 (89%)</td>
                        <td align="left" rowspan="1" colspan="1">36 (88%)</td>
                        <td align="left" rowspan="1" colspan="1">33 (66%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Immediately prestudy drug</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">TIMI coronary flow grade<xref ref-type="fn" rid="jah34769-note-0006">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">5 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (5%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">41 (29%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (24%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (35%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">95 (67%)</td>
                        <td align="left" rowspan="1" colspan="1">35 (69%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (71%)</td>
                        <td align="left" rowspan="1" colspan="1">31 (63%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">TIMI thrombus grade<xref ref-type="fn" rid="jah34769-note-0006">a</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">12 (9%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (5%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">21 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">62 (44%)</td>
                        <td align="left" rowspan="1" colspan="1">21 (41%)</td>
                        <td align="left" rowspan="1" colspan="1">21 (51%)</td>
                        <td align="left" rowspan="1" colspan="1">20 (41%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">46 (33%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (29%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">20 (41%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Study drug administration</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thrombectomy catheter</td>
                        <td align="left" rowspan="1" colspan="1">106 (74%)</td>
                        <td align="left" rowspan="1" colspan="1">39 (74%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (71%)</td>
                        <td align="left" rowspan="1" colspan="1">38 (76%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Guide catheter</td>
                        <td align="left" rowspan="1" colspan="1">35 (24%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (25%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (22%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                        <td align="left" rowspan="1" colspan="1">3 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Poststudy drug</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">PCI with stent implant</td>
                        <td align="left" rowspan="1" colspan="1">144 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">53 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">41 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">50 (100%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Total stent length, mm</td>
                        <td align="left" rowspan="1" colspan="1">35.6Â±13.2</td>
                        <td align="left" rowspan="1" colspan="1">33.6Â±12.2</td>
                        <td align="left" rowspan="1" colspan="1">38.1Â±14.6</td>
                        <td align="left" rowspan="1" colspan="1">35.8Â±13.0</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Poststent dilatation</td>
                        <td align="left" rowspan="1" colspan="1">133 (92%)</td>
                        <td align="left" rowspan="1" colspan="1">46 (87%)</td>
                        <td align="left" rowspan="1" colspan="1">41 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">46 (92%)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" rowspan="1">Acute therapy following first medical contact<xref ref-type="fn" rid="jah34769-note-0007">b</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Aspirin loading dose</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">300Â mg</td>
                        <td align="left" rowspan="1" colspan="1">142 (99%)</td>
                        <td align="left" rowspan="1" colspan="1">53 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">40 (98%)</td>
                        <td align="left" rowspan="1" colspan="1">49 (98%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">None</td>
                        <td align="left" rowspan="1" colspan="1">2 (1%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="5" rowspan="1">Additional antiplatelet medication</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">None</td>
                        <td align="left" rowspan="1" colspan="1">2 (1%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clopidogrel</td>
                        <td align="left" rowspan="1" colspan="1">87 (60%)</td>
                        <td align="left" rowspan="1" colspan="1">27 (51%)</td>
                        <td align="left" rowspan="1" colspan="1">28 (68%)</td>
                        <td align="left" rowspan="1" colspan="1">32 (64%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ticagrelor</td>
                        <td align="left" rowspan="1" colspan="1">55 (38%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (49%)</td>
                        <td align="left" rowspan="1" colspan="1">12 (29%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (34%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Prasugrel</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unfractionated heparin, U median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">11Â 500 (10Â 000, 15Â 000)</td>
                        <td align="left" rowspan="1" colspan="1">10Â 000 (10Â 000, 14Â 000)</td>
                        <td align="left" rowspan="1" colspan="1">12Â 000 (10Â 000, 15Â 000)</td>
                        <td align="left" rowspan="1" colspan="1">12Â 000 (10Â 000, 15Â 375)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intravenous morphine</td>
                        <td align="left" rowspan="1" colspan="1">134 (93%)</td>
                        <td align="left" rowspan="1" colspan="1">48 (91%)</td>
                        <td align="left" rowspan="1" colspan="1">38 (93%)</td>
                        <td align="left" rowspan="1" colspan="1">48 (96%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Inhaled oxygen</td>
                        <td align="left" rowspan="1" colspan="1">20 (14%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (17%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Glycoprotein IIb/IIIa antagonist</td>
                        <td align="left" rowspan="1" colspan="1">8 (6%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (12%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspiration thrombectomy</td>
                        <td align="left" rowspan="1" colspan="1">23 (16%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (15%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (14%)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34769-ntgp-0003">
                    <fn id="jah34769-note-0005">
                      <p>Data are meanÂ±SD, or n (%), unless otherwise stated. IQR indicates interquartile range; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; RCA, right coronary artery; TIMI, Thrombolysis in Myocardial Infarction.</p>
                    </fn>
                    <fn id="jah34769-note-0006">
                      <label>a</label>
                      <p>Missing data: TIMI coronary flow grade and TIMI thrombus grade immediately prestudy drug, 3 subjects (2 placebo, 1 alteplase 20Â mg group).</p>
                    </fn>
                    <fn id="jah34769-note-0007">
                      <label>b</label>
                      <p>None of the patients received intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig fig-type="Figure" xml:lang="en" id="jah34769-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>DiagramÂ showing patient recruitment, randomization, and flow through the Tâ<styled-content style="fixed-case" toggle="no">TIME</styled-content> physiology substudy. <styled-content style="fixed-case" toggle="no">CMR</styled-content> indicates cardiovascular magnetic resonance; STEMI, STâsegmentâelevation myocardial infarction; TâTIME, A Trial of LowâDose Adjunctive Alteplase During Primary PCI.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e014066-g002"/>
                </fig>
                <p>At initial coronary angiography, TIMI flow grade was â¤1 in 124 (88%) patients and 2 in 20 (12%) patients. The thrombus grade at presentation was 5 (occluded vessel) in 116 (81%) patients, 4 (thrombus dimension &gt;2 vessel diameters) in 25 (17%) patients, and 3 (thrombus dimension &gt;1/2 and &lt;2 vessel diameters) in 3 (2%) patients. The residual thrombus grade postreperfusion immediately before study drug delivery was 4 in 46 (33%) patients, 3 in 62 (44%) patients, 2 in 21 (15%) patients, and 1 in 12 (9%) patients. All but one of the patients received the study intervention according to the protocol.</p>
              </sec>
              <sec id="jah34769-sec-0022">
                <title>Primary Physiology End Point</title>
                <p>Median IMR for the entire population was 29.5 (IQR, 17.0, 55.0). Fortyâeight percent (n=69) had an IMR &gt;32 at the end of the procedure, and 40% (n=57) had an IMR &gt;40. On logistic regression analysis, older age was the only baseline characteristic that independently predicted an IMR &gt;32 (mean age was 57.2Â±9.5 in those with IMR â¤32 and mean age was 61.7Â±11.2 in those with IMR &gt;32). Overall, IMR did not differ between the alteplase groups (10, 20Â mg) and placebo (alteplase 10Â mg: median 22.0 [IQR, 17.0, 42.0] versus placebo, 33.0 [17.0, 57.0]; relative difference, 0.79 [95% CI, 0.58, 1.07]; <italic>P</italic>=0.125; alteplase 20Â mg: 37.0 [20.0â57.8] versus placebo, 33.0; relative difference, 1.04 [95% CI, 0.78â1.38]; <italic>P</italic>=0.801; TableÂ <xref rid="jah34769-tbl-0003" ref-type="table">3</xref>).</p>
                <table-wrap id="jah34769-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Coronary Physiology End Points</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Treatment Group</th>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Treatment Effect</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">All (n=144)</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Placebo (n=53)</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Alteplase 10Â mg (n=41)</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Alteplase 20Â mg (n=50)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">20Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">10Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">10 or 20Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Trend With Dose</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IMR<xref ref-type="fn" rid="jah34769-note-0009">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">29.5 (17.0, 55.0)</td>
                        <td align="left" rowspan="1" colspan="1">33.0 (17.0, 57.0)</td>
                        <td align="left" rowspan="1" colspan="1">22.0 (17.0, 42.0)</td>
                        <td align="left" rowspan="1" colspan="1">37.0 (20.0, 57.8)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.04 (0.78, 1.38)</p>
                          <p><italic>P</italic>=0.801</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.79 (0.58, 1.07)</p>
                          <p><italic>P</italic>=0.125</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.92 (0.71, 1.18)</p>
                          <p><italic>P</italic>=0.505</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.02 (0.88, 1.17)</p>
                          <p><italic>P</italic>=0.824</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IMR &gt;40<xref ref-type="fn" rid="jah34769-note-0010">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">57 (40%)</td>
                        <td align="left" rowspan="1" colspan="1">24 (45%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (44%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.93 (0.42, 2.05)</p>
                          <p><italic>P</italic>=0.864</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.42 (0.17, 1.02)</p>
                          <p><italic>P</italic>=0.054</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.66 (0.33, 1.34)</p>
                          <p><italic>P</italic>=0.251</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.96 (0.64, 1.43)</p>
                          <p><italic>P</italic>=0.840</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IMR &gt;32<xref ref-type="fn" rid="jah34769-note-0010">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">69 (48%)</td>
                        <td align="left" rowspan="1" colspan="1">27 (51%)</td>
                        <td align="left" rowspan="1" colspan="1">15 (37%)</td>
                        <td align="left" rowspan="1" colspan="1">27 (54%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.12 (0.51, 2.44)</p>
                          <p><italic>P</italic>=0.774</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.54 (0.23, 1.24)</p>
                          <p><italic>P</italic>=0.147</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.81 (0.41, 1.60)</p>
                          <p><italic>P</italic>=0.546</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.05 (0.71, 1.55)</p>
                          <p><italic>P</italic>=0.794</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CFR<xref ref-type="fn" rid="jah34769-note-0009">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (1.1, 2.0)</td>
                        <td align="left" rowspan="1" colspan="1">1.3 (1.1, 1.8)</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (1.1, 1.9)</td>
                        <td align="left" rowspan="1" colspan="1">1.4 (1.1, 2.0)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.03 (0.88, 1.20)</p>
                          <p><italic>P</italic>=0.732</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.01 (0.86, 1.19)</p>
                          <p><italic>P</italic>=0.900</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.02 (0.89, 1.17)</p>
                          <p><italic>P</italic>=0.777</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.01 (0.94, 1.09)</p>
                          <p><italic>P</italic>=0.732</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CFR â¤2<xref ref-type="fn" rid="jah34769-note-0010">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">115 (80%)</td>
                        <td align="left" rowspan="1" colspan="1">44 (83%)</td>
                        <td align="left" rowspan="1" colspan="1">31 (76%)</td>
                        <td align="left" rowspan="1" colspan="1">40 (80%)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.23 (0.45, 3.36)</p>
                          <p><italic>P</italic>=0.680</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.62 (0.59, 3.36)</p>
                          <p><italic>P</italic>=0.680</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.40 (0.58, 3.36)</p>
                          <p><italic>P</italic>=0.451</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.11 (0.68, 1.79)</p>
                          <p><italic>P</italic>=0.681</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RRR<xref ref-type="fn" rid="jah34769-note-0009">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.3, 2.3)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.3, 2.2)</td>
                        <td align="left" rowspan="1" colspan="1">1.6 (1.4, 2.6)</td>
                        <td align="left" rowspan="1" colspan="1">1.8 (1.3, 2.4)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.02 (0.87, 1.20)</p>
                          <p><italic>P</italic>=0.795</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.04 (0.88, 1.23)</p>
                          <p>p=0.658</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.03 (0.90, 1.18)</p>
                          <p>=0.685</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.01 (0.93, 1.09)</p>
                          <p>0.790</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" colspan="9" rowspan="1">Waveform<xref ref-type="fn" rid="jah34769-note-0011">c</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unimodal (narrow)</td>
                        <td align="left" rowspan="1" colspan="1">75 (52%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (49%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (54%)</td>
                        <td align="left" rowspan="1" colspan="1">27 (54%)</td>
                        <td align="left" rowspan="3" colspan="1">
                          <p>0.98 (0.46, 2.06)</p>
                          <p><italic>P</italic>=0.956</p>
                        </td>
                        <td align="left" rowspan="3" colspan="1">
                          <p>1.00 (0.45, 2.20)</p>
                          <p><italic>P</italic>=0.999</p>
                        </td>
                        <td align="left" rowspan="3" colspan="1">
                          <p>0.99 (0.52, 1.89)</p>
                          <p><italic>P</italic>=0.972</p>
                        </td>
                        <td align="left" rowspan="3" colspan="1">
                          <p>0.99 (0.68, 1.44)</p>
                          <p><italic>P</italic>=0.957</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unimodal (wide)</td>
                        <td align="left" rowspan="1" colspan="1">56 (39%)</td>
                        <td align="left" rowspan="1" colspan="1">25 (47%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (34%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (34%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bimodal</td>
                        <td align="left" rowspan="1" colspan="1">13 (9%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (12%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVEDP, mmÂ Hg<xref ref-type="fn" rid="jah34769-note-0012">d</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">17.0 (12.0, 20.8)</td>
                        <td align="left" rowspan="1" colspan="1">16.5 (13.2, 19.0)</td>
                        <td align="left" rowspan="1" colspan="1">19.0 (13.2, 22.8)</td>
                        <td align="left" rowspan="1" colspan="1">15.0 (12.0, 18.8)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.89 (0.75, 1.05)</p>
                          <p><italic>P</italic>=0.172</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">1.05 (0.88, 1.25) <italic>P</italic>=0.579</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.96 (0.83, 1.12)</p>
                          <p><italic>P</italic>=0.609</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.94 (0.87, 1.03)</p>
                          <p><italic>P</italic>=0.184</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34769-ntgp-0004">
                    <fn id="jah34769-note-0008">
                      <p>Data are median (IQR) or n (%). Betweenâgroup comparisons derived from linear, logistic, or ordinal logistic regression models, adjusted for location of MI (see footnotes). CFR indicates coronary flow reserve; IMR, index of microcirculatory resistance; IQR, interquartile range; LVEDP, left ventricular endâdiastolic pressure; MI, myocardial infarction; RRR, resistive reserve ratio.</p>
                    </fn>
                    <fn id="jah34769-note-0009">
                      <label>a</label>
                      <p>Data analyzed on logarithmic scale. Treatment effect estimates reported as relative differences between groups, with 95% CI and <italic>P</italic> value, from linear regression model adjusted for location of MI.</p>
                    </fn>
                    <fn id="jah34769-note-0010">
                      <label>b</label>
                      <p>Treatment effect estimates reported as odds ratios between groups, with 95% CI and <italic>P</italic> value, from logistic regression model adjusted for location of MI.</p>
                    </fn>
                    <fn id="jah34769-note-0011">
                      <label>c</label>
                      <p>Treatment effect estimates reported as odds ratio between groups, with 95% CI and <italic>P</italic> value, from ordinal logistic regression model adjusted for location of MI.</p>
                    </fn>
                    <fn id="jah34769-note-0012">
                      <label>d</label>
                      <p>Missing data: LVEDP, 18 subjects (7 placebo, 3 alteplase 10Â mg, and 8 alteplase 20Â mg group).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The intraclass correlation coefficient (ICC) for IMR, assessed from 30 consecutive patients, showed excellent intrarater reliability (ICC, 0.998 [95% CI, 0.997, 0.999]) and interârater reliability (ICC, 0.999 [95% CI, 0.998, 0.999]). The mean difference between repeated IMR measurements from 12 patients was 6.33 (<italic>P</italic>=0.076).</p>
              </sec>
              <sec id="jah34769-sec-0023">
                <title>Secondary Physiology End Points</title>
                <p>Median CFR for the population was 1.4 (IQR, 1.1, 2.0). At the end of the procedure, 115 (88%) patients had a CFR â¤2.0. The median RRR for the entire population was 1.7 (IQR, 1.3, 2.3). Overall, neither CFR nor RRR differed with alteplase versus placebo (TableÂ <xref rid="jah34769-tbl-0003" ref-type="table">3</xref>). The mean difference between repeated CFR measurements from 9 patients was 0.07 (<italic>P</italic>=0.659). The mean difference between repeated RRR measurements from 9 patients was â0.04 (<italic>P</italic>=0.860). The ICC for RRR, assessed from 30 consecutive patients, showed excellent intrarater reliability (ICC, 0.988 [95% CI, 0.974, 0.994]) and interârater reliability (ICC, 0.988 [95% CI, 0.975, 0.994]).</p>
                <p>Thermodilution waveforms or LV endâdiastolic pressure did not differ with alteplase versus placebo.</p>
              </sec>
              <sec id="jah34769-sec-0024">
                <title>Angiographic, ECG, and Troponin Results</title>
                <p>As in the main trial, there were no differences in final TIMI coronary flow grade or TIMI frame count between treatment groups (TableÂ <xref rid="jah34769-tbl-0004" ref-type="table">4</xref>). TIMI myocardial perfusion grade was higher in the alteplase 20Â mg group compared with the placebo group (odds ratio, 2.16 [95% CI, 1.04, 4.49]; <italic>P</italic>=0.039). There was no difference in TIMI myocardial perfusion grade between the alteplase 10Â mg versus placebo group (odds ratio, 1.32 [95% CI, 0.60, 2.92]; <italic>P</italic>=0.496). Percent STâsegment resolution 60Â minutes postreperfusion did not differ with alteplase versus placebo (TableÂ <xref rid="jah34769-tbl-0004" ref-type="table">4</xref>). Troponin T under the curve (0â24Â hours) did not differ with alteplase versus placebo (TableÂ <xref rid="jah34769-tbl-0004" ref-type="table">4</xref>).</p>
                <table-wrap id="jah34769-tbl-0004" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 4</label>
                  <caption>
                    <p>ECG, Angiographic, and Troponin End Points</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Treatment Group</th>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Treatment Effect</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">All (n=144)</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Placebo (n=53)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Alteplase</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Alteplase</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">20Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">10Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">10 or 20Â mg vs Placebo</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Trend With Dose</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">10Â mg (n=41)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">20Â mg (n=50)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Estimate (95% CI) <italic>P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Absolute % STâsegment resolution 60Â min<xref ref-type="fn" rid="jah34769-note-0014">a</xref>
<sup>,</sup>
<xref ref-type="fn" rid="jah34769-note-0015">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">46.6 (40.9)</td>
                        <td align="left" rowspan="1" colspan="1">45.1 (37.8)</td>
                        <td align="left" rowspan="1" colspan="1">45.7 (43.8)</td>
                        <td align="left" rowspan="1" colspan="1">48.8 (42.4)</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>4.15 (â11.71, 20.02)</p>
                          <p><italic>P</italic>=0.608</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.32 (â15.53, 18.16)</p>
                          <p><italic>P</italic>=0.878</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.89 (â11.04, 16.83)</p>
                          <p><italic>P</italic>=0.684</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.08(â5.83, 9.98)</p>
                          <p><italic>P</italic>=0.607</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TIMI flow grade postâPCI<xref ref-type="fn" rid="jah34769-note-0016">c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.70 (0.51, 5.69)</p>
                          <p><italic>P</italic>=0.391</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.43 (0.42, 4.84)</p>
                          <p><italic>P</italic>=0.565</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.57 (0.57, 4.32)</p>
                          <p><italic>P</italic>=0.387</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.31 (0.71, 2.41)</p>
                          <p><italic>P</italic>=0.383</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">3 (2%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4%)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">1 (2%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">15 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (11%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (12%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">126 (88%)</td>
                        <td align="left" rowspan="1" colspan="1">45 (85%)</td>
                        <td align="left" rowspan="1" colspan="1">36 (88%)</td>
                        <td align="left" rowspan="1" colspan="1">45 (90%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TIMI MPG postâPCI<xref ref-type="fn" rid="jah34769-note-0016">c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">42 (29)</td>
                        <td align="left" rowspan="1" colspan="1">18 (34)</td>
                        <td align="left" rowspan="1" colspan="1">15 (37)</td>
                        <td align="left" rowspan="1" colspan="1">9 (18)</td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>2.16 (1.04, 4.49)</p>
                          <p><italic>P</italic>=0.039 Â§</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.32 (0.60, 2.92)</p>
                          <p><italic>P</italic>=0.496</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.75 (0.91, 3.37)</p>
                          <p><italic>P</italic>=0.091</p>
                        </td>
                        <td align="left" rowspan="4" colspan="1">
                          <p>1.47 (1.02, 2.21)</p>
                          <p><italic>P</italic>=0.039 Â§</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">3 (2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (6)</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">60 (42)</td>
                        <td align="left" rowspan="1" colspan="1">19 (36)</td>
                        <td align="left" rowspan="1" colspan="1">15 (37)</td>
                        <td align="left" rowspan="1" colspan="1">26 (52)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">39 (27)</td>
                        <td align="left" rowspan="1" colspan="1">13 (25)</td>
                        <td align="left" rowspan="1" colspan="1">11 (27)</td>
                        <td align="left" rowspan="1" colspan="1">15 (30)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TFC postâPCI, median (IQR)<xref ref-type="fn" rid="jah34769-note-0018">d</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">18.0 (14.0, 26.0)</td>
                        <td align="left" rowspan="1" colspan="1">18.0 (14.0, 26.0)</td>
                        <td align="left" rowspan="1" colspan="1">16.5 (14.0, 22.4)</td>
                        <td align="left" rowspan="1" colspan="1">22.0 (14.0, 24.5)</td>
                        <td align="left" rowspan="1" colspan="1">1.03 (0.84, 1.27) <italic>P</italic>=0.774</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.89 (0.72, 1.11)</p>
                          <p><italic>P</italic>=0.311</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.97 (0.80, 1.16)</p>
                          <p><italic>P</italic>=0.713</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.01 (0.91, 1.13)</p>
                          <p><italic>P</italic>=0.789</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Troponin T AUC 0 to 24Â h (mg/L)<xref ref-type="fn" rid="jah34769-note-0016">c</xref>
<sup>,</sup>
<xref ref-type="fn" rid="jah34769-note-0018">d</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">125.6 (143.2)</td>
                        <td align="left" rowspan="1" colspan="1">115.6 (139.5)</td>
                        <td align="left" rowspan="1" colspan="1">130.8 (142.4)</td>
                        <td align="left" rowspan="1" colspan="1">131.7 (150.5)</td>
                        <td align="left" rowspan="1" colspan="1">1.39 (0.83, 2.34) <italic>P</italic>=0.213</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.56 (0.91, 2.67)</p>
                          <p><italic>P</italic>=0.110</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.46 (0.93, 2.30)</p>
                          <p><italic>P</italic>=0.098</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.18 (0.91, 1.53)</p>
                          <p><italic>P</italic>=0.206</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34769-ntgp-0005">
                    <fn id="jah34769-note-0013">
                      <p>Data are meanÂ±SD, or n (%), unless otherwise stated. Betweenâgroup comparisons derived from linear, logistic, or ordinal logistic regression models, adjusted for location of MI (see footnotes). AUC indicates area under the curve; IQR, interquartile range; MI, myocardial infarction; MPG, myocardial perfusion grade; PCI, percutaneous coronary intervention; TFC, TIMI frame count; TIMI, Thrombolysis in Myocardial Infarction.</p>
                    </fn>
                    <fn id="jah34769-note-0014">
                      <label>a</label>
                      <p>Treatment effect estimates reported as mean differences between groups, with 95% CI and <italic>P</italic> value, from linear regression model adjusted for MI location.</p>
                    </fn>
                    <fn id="jah34769-note-0015">
                      <label>b</label>
                      <p>Missing data: STâsegment resolution 60Â min, 3 subjects (2 placebo, 1 alteplase 10Â mg group). Troponin T AUC, 21 subjects (8 placebo, 5 alteplase 10Â mg, and 8 alteplase 20Â mg group).</p>
                    </fn>
                    <fn id="jah34769-note-0016">
                      <label>c</label>
                      <p>Treatment effect estimates reported as odds ratio between groups, with 95% CI and <italic>P</italic> value, from a proportional odds logistic regression model, adjusting for MI location.</p>
                    </fn>
                    <fn id="jah34769-note-0018">
                      <label>d</label>
                      <p>Data analyzed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups, with 95% CI and <italic>P</italic> value, from linear regression model adjusted for MI location.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah34769-sec-0025">
                <title>Cardiovascular Magnetic Resonance Imaging Results</title>
                <p>CMR was performed in 140 patients (97%) from 2 to 7Â days after enrollment and in 135 patients (94%) at 3Â months. Overall, there was no difference in microvascular obstruction or myocardial hemorrhage presence or extent, infarct size, myocardial salvage, LV ejection fraction, or volumes with alteplase versus placebo (TableÂ <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
              </sec>
              <sec id="jah34769-sec-0026">
                <title>Coagulation and Hematological Variables</title>
                <p>There was an alteplase doseârelated increase in systemic concentrations of fibrin Dâdimer, reflecting fibrinoylsis, and prothrombin fragment F<sub>1+2</sub>, reflecting activation of the clotting system, and a reduction in plasminogen, reflecting the intended effect of alteplase (TableÂ <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S2</xref>). Systemic concentrations of fibrinogen and hemoglobin were similar between treatment groups (TableÂ <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S2</xref>), indicating that effects of alteplase were localized to the heart.</p>
              </sec>
              <sec id="jah34769-sec-0027">
                <title>Clinical Outcomes</title>
                <p>Followâup information was available for all patients at 3Â months postâSTEMI. Major adverse cardiac events occurred in 20 patients by 3Â months, of whom 7 received placebo, 7 received alteplase 10Â mg, and 6 received alteplase 20Â mg. Three patients died during the 3âmonth followâup period, of whom 1 received alteplase 10Â mg and 2 received alteplase 20Â mg. There were 17 unplanned hospitalizations for heart failure by 3Â months (7 in the placebo group, 6 in the alteplase 10Â mg group, and 4 in the alteplase 20Â mg group).</p>
              </sec>
              <sec id="jah34769-sec-0028">
                <title>Subgroup Analyses</title>
                <p>Treatment effect estimates for IMR, CFR, and RRR measured in the culprit coronary artery at the end of PCI in the prespecified subgroups, based on postulated pathophysiological mechanisms, are shown in FigureÂ <xref rid="jah34769-fig-0003" ref-type="fig">3</xref>, TableÂ <xref rid="jah34769-tbl-0005" ref-type="table">5</xref>, and Tables <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S3 through S4</xref>.</p>
                <fig fig-type="Figure" xml:lang="en" id="jah34769-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Forest plots showing treatment effect estimates and interaction <italic>P</italic> values for <styled-content style="fixed-case" toggle="no">IMR</styled-content> (index of microcirculatory resistance), <styled-content style="fixed-case" toggle="no">CFR</styled-content> (coronary flow reserve), and <styled-content style="fixed-case" toggle="no">RRR</styled-content> (resistive reserve ratio) in subgroups for ischemic time and <styled-content style="fixed-case" toggle="no">TIMI</styled-content> (Thrombolysis in Myocardial Infarction) coronary flow grade and thrombus grade immediately before study drug delivery.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JAH3-9-e014066-g003"/>
                </fig>
                <table-wrap id="jah34769-tbl-0005" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 5</label>
                  <caption>
                    <p>IMR, CFR, and RRR, Microvascular Obstruction and Myocardial Hemorrhage in Subgroups of Ischemic Time</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" valign="top" colspan="1">Ischemic Time</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Placebo [n=53]</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Alteplase 10Â mg [n=41]</th>
                        <th align="left" rowspan="2" valign="top" colspan="1">Alteplase 20Â mg [n=50]</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Treatment Effect</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Interaction <italic>P</italic> Value (treatment as 3âlevel categorical variable)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Treatment Effect</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Interaction <italic>P</italic> Value (treatment as 2âlevel categorical variable)</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Treatment Effect</th>
                        <th align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Interaction <italic>P</italic> Value (treatment as per 10Â mg increase in dose)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">20Â mg vs Placebo</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">10Â mg vs Placebo</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">10 or 20Â mg vs Placebo</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Trend With Dose</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="11" rowspan="1">IMR</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>45.0 (23.0, 53.2)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>29.0 (17.0, 36.0)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>19.5 (15.0, 22.8)</p>
                          <p>[8]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.52 (0.26, 1.04)</p>
                          <p><italic>P</italic>=0.064</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.79 (0.43, 1.46)</p>
                          <p><italic>P</italic>=0.454</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.172</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.68 (0.39, 1.19)</p>
                          <p><italic>P</italic>=0.173</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.367</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.73 (0.52, 1.02)</p>
                          <p><italic>P</italic>=0.068</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.097</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥2, &lt;4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>31.5 (15.5, 51.0)</p>
                          <p>[30]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>24.0 (15.0, 42.0)</p>
                          <p>[17]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>39.5 (20.0, 61.2)</p>
                          <p>[32]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.24 (0.86, 1.79)</p>
                          <p><italic>P</italic>=0.250</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.82 (0.53, 1.27)</p>
                          <p><italic>P</italic>=0.364</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.07 (0.76, 1.51)</p>
                          <p><italic>P</italic>=0.685</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.12 (0.93, 1.34)</p>
                          <p><italic>P</italic>=0.243</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>28.0 (19.0, 60.0)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>19.0 (17.0, 34.0)</p>
                          <p>[11]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>51.0 (26.8, 59.0)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.07 (0.58, 1.96)</p>
                          <p><italic>P</italic>=0.837</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.70 (0.39, 1.27)</p>
                          <p><italic>P</italic>=0.238</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.86 (0.51, 1.44)</p>
                          <p><italic>P</italic>=0.556</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.02 (0.75, 1.38)</p>
                          <p><italic>P</italic>=0.918</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="11" rowspan="1">CFR</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.2 (1.1, 1.7)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.4 (1.0, 1.8)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.0 (1.8, 2.3)</p>
                          <p>[8]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.59 (1.11, 2.27)</p>
                          <p><italic>P</italic>=0.012*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.94 (0.68, 1.29)</p>
                          <p><italic>P</italic>=0.686</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.013*</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.14(0.85, 1.55)</p>
                          <p><italic>P</italic>=0.379</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.652</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.24 (1.04, 1.49)</p>
                          <p><italic>P</italic>=0.019*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.038*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥2, &lt;4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.3 (1.1, 1.8)</p>
                          <p>[30]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.3 (1.2, 1.8)</p>
                          <p>[17]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.4 (1.2, 2.0)</p>
                          <p>[32]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.00 (0.82, 1.21)</p>
                          <p><italic>P</italic>=0.987</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.03 (0.82, 1.30)</p>
                          <p><italic>P</italic>=0.791</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.01 (0.84, 1.21)</p>
                          <p><italic>P</italic> =0.915</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.00 (0.91, 1.10)</p>
                          <p>0.984</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.7 (1.4, 2.0)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.8 (1.3, 2.6)</p>
                          <p>[11]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.2 (1.0, 1.6)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.82 (0.60, 1.13)</p>
                          <p><italic>P</italic>=0.224</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.08 (0.79, 1.47)</p>
                          <p><italic>P</italic>=0.636</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.95 (0.72, 1.25)</p>
                          <p><italic>P</italic>=0.697</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.91 (0.78, 1.07)</p>
                          <p><italic>P</italic>=0.264</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="11" rowspan="1">RRR</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.5 (1.3, 1.9)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.6 (1.1, 2.2)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.2 (2.0, 2.6)</p>
                          <p>[8]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.52 (1.05, 2.22)</p>
                          <p><italic>P</italic>=0.028*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.93 (0.66, 1.29)</p>
                          <p><italic>P</italic>=0.647</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.026*</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.12 (0.82, 1.53)</p>
                          <p><italic>P</italic>=0.481</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.827</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.22 (1.01, 1.47)</p>
                          <p><italic>P</italic>=0.041*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.093</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥2, &lt;4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.6 (1.3, 2.2)</p>
                          <p>[30]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.6 (1.5, 2.6)</p>
                          <p>[17]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.6 (1.3, 2.2)</p>
                          <p>[32]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.98 (0.80, 1.20)</p>
                          <p><italic>P</italic>=0.848</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.10 (0.87, 1.40)</p>
                          <p><italic>P</italic>=0.435</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.02 (0.85, 1.23)</p>
                          <p><italic>P</italic>=0.833</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.99 (0.89, 1.1.0)</p>
                          <p><italic>P</italic>=0.838</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.9 (1.6, 2.3)</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.3 (1.6, 2.8)</p>
                          <p>[11]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.4 (1.0, 2.5)</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.86 (0.61, 1.20)</p>
                          <p><italic>P</italic>=0.367</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.11 (0.80, 1.54)</p>
                          <p><italic>P</italic>=0.518</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.98 (0.74, 1.31)</p>
                          <p><italic>P</italic>=0.907</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.93 (0.79, 1.1.0)</p>
                          <p><italic>P</italic>=0.420</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2Â hours [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.1Â±3.9</p>
                          <p>[9]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.2Â±4.0</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0Â±0.0</p>
                          <p>[8]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.87 (â2.07, 0.33)</p>
                          <p><italic>P</italic>=0.155</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.03 (â1.10, 1.03)</p>
                          <p><italic>P</italic>=0.950</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.039*</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.35 (â1.34, 0.64)</p>
                          <p><italic>P</italic>=0.484</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.089</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.42(â1.02, 0.17)</p>
                          <p><italic>P</italic>=0.161</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.010*</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥2, &lt;4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.4Â±3.3</p>
                          <p>[29]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.6Â±4.4</p>
                          <p>[17]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.8Â±5.9</p>
                          <p>[31]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.14 (â0.77, 0.50)</p>
                          <p><italic>P</italic>=0.676</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.14 (â0.90, 0.61)</p>
                          <p><italic>P</italic>=0.715</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.14 (â0.72, 0.45)</p>
                          <p><italic>P</italic>=0.643</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.07 (â0.38, 0.25)</p>
                          <p><italic>P</italic>=0.676</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.9Â±1.6</p>
                          <p>[13]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.8Â±4.5</p>
                          <p>[11]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>6.0 Â±6.6</p>
                          <p>[9]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.47 (0.40, 0.54)</p>
                          <p><italic>P</italic>=0.007*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.49 (â0.52, 1.50)</p>
                          <p><italic>P</italic>=0.337</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.93 (0.05, 1.82)</p>
                          <p>0.039*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.72 (0.19, 1.25)</p>
                          <p><italic>P</italic>=0.007*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;2Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.5Â±0.9</p>
                          <p>[7]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.7Â±3.8</p>
                          <p>[11]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.0Â±0.0</p>
                          <p>[8]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.51 (â4.44, 3.42)</p>
                          <p><italic>P</italic>=0.800</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.20 (â2.48, 4.87)</p>
                          <p><italic>P</italic>=0.523</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.153</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.48 (â2.91, 3.86)</p>
                          <p><italic>P</italic> =0.783</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.392</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.30 (â2.25, 1.66)</p>
                          <p><italic>P</italic>=0.766</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.080</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥2, &lt;4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.2Â±3.3</p>
                          <p>[28]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.7Â±4.4</p>
                          <p>[15]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.2Â±4.9</p>
                          <p>[31]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.06 (â2.05, 1.92)</p>
                          <p><italic>P</italic>=0.950</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.41 (â2.04, 2.86)</p>
                          <p><italic>P</italic>=0.741</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.09 (â1.75, 1.93)</p>
                          <p><italic>P</italic>=0.926</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>â0.04 (â1.02, 0.95)</p>
                          <p><italic>P</italic>=0.941</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">â¥4Â h [n]</td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.8Â±1.7</p>
                          <p>[12]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>1.6Â±3.1</p>
                          <p>[10]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>5.1Â±5.9</p>
                          <p>[9]</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>4.25 (0.88, 7.61)</p>
                          <p><italic>P</italic>=0.013*</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>0.80 (â2.46, 4.06)</p>
                          <p><italic>P</italic>=0.632</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.42 (â0.41, 5.25)</p>
                          <p><italic>P</italic>=0.094</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">
                          <p>2.06 (0.39, 3.73)</p>
                          <p><italic>P</italic>=0.016</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah34769-ntgp-0006">
                    <fn id="jah34769-note-0019">
                      <p>Data are median (IQR) or meanÂ±SD. Coronary physiology data were analyzed on a logarithmic scale, with treatment effect estimates reported as relative differences and 95% CIs with <italic>P</italic> values, derived from linear regression, adjusted for location of MI. Microvascular obstruction (% LV) was analyzed on a square root scale, with treatment effect estimates reported as mean differences and 95% CIs with <italic>P</italic> values, derived from linear regression, adjusted for location of MI. CFR indicates coronary flow reserve; IMR, index of microcirculatory resistance; IQR, interquartile range; LV, left ventricular; MI, myocardial infarction; RRR, resistive reserve ratio.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="jah34769-sec-0029">
                  <title>Ischemic time</title>
                  <p>There was no interaction between ischemic time and alteplase with IMR (TableÂ <xref rid="jah34769-tbl-0005" ref-type="table">5</xref>). In patients with an ischemic time &lt;2Â hours, median IMR was 45.0 (23.0, 53.2) with placebo, 29.0 (17.0, 36.0) with alteplase 10Â mg, and 19.5 (15.0, 22.8) with alteplase 20Â mg. In patients with an ischemic time â¥4Â hours, median IMR was 28.0 (19.0, 60.0) with placebo, 19.0 (17.0, 34.0) with alteplase 10Â mg, and 51.0 (26.8, 59.0) with alteplase 20Â mg.</p>
                  <p>Interactions were observed between ischemic time and alteplase for CFR (<italic>P</italic>=0.013) and RRR (<italic>P</italic>=0.026; FigureÂ <xref rid="jah34769-fig-0003" ref-type="fig">3</xref>; TableÂ <xref rid="jah34769-tbl-0005" ref-type="table">5</xref>). In patients with ischemic times &lt;2Â hours, median CFR was higher with alteplase (placebo, 1.2 [1.1, 1.7]; alteplase 10Â mg, 1.4 [1.0, 1.8]; alteplase 20Â mg, 2.0 [1.8, 2.3]). RRR was also higher with alteplase in patients with an ischemic time &lt;2Â hours (placebo, 1.5 [1.3, 1.9]; alteplase 10Â mg, 1.6 [1.1, 2.2]; alteplase 20Â mg, 2.2 [2.0, 2.6]). In patients with an ischemic time â¥4Â hours, RRR was 2.0 (1.4, 2.7) with placebo, 2.3 (1.6, 2.8) with alteplase 10Â mg, and 1.4 (1.0, 2.5) with alteplase 20Â mg. In those with an ischemic time â¥4Â hours, CFR was 1.7 (1.4, 2.0) with placebo, 1.8 (1.3, 2.6) with alteplase 10Â mg, and 1.2 (1.0, 1.6) with alteplase 20Â mg.</p>
                  <p>An interaction occurred between ischemic time and alteplase for amount of microvascular obstruction (<italic>P</italic>=0.022). In patients with an ischemic time â¥4Â hours, alteplase increased the mean extent of microvascular obstruction: placebo (0.89 Â± 1.65%), alteplase 10Â mg (2.77 Â± 4.54%), and alteplase 20Â mg (5.97 Â± 6.58%). In those with an ischemic time &lt;2Â hours, mean amount of microvascular obstruction was: 2.06 Â± 3.93% with placebo, 2.22 Â± 3.98% with alteplase 10Â mg, and 0.00 Â± 0.00% with alteplase 20Â mg.</p>
                </sec>
                <sec id="jah34769-sec-0030">
                  <title>TIMI flow and thrombus grades prestudy drug</title>
                  <p>There was no interaction between treatment group and IMR, CFR, or RRR in the following subgroups: (1) TIMI coronary flow grade immediately prestudy drug dichotomized by â¤2 or 3; (2) TIMI thrombus grade immediately prestudy drug dichotomized by â¤2 or â¥3 (FigureÂ <xref rid="jah34769-fig-0003" ref-type="fig">3</xref> and Tables <xref rid="jah34769-sup-0001" ref-type="supplementary-material">S3 and S4</xref>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="jah34769-sec-0031">
              <title>Discussion</title>
              <p>The main finding is that overall microvascular function, assessed by IMR, CFR, and RRR, did not differ between alteplase and placebo groups.</p>
              <p>The lack of an overall treatment effect on microvascular function in the culprit artery contrasts with the findings of Sezer etÂ al.<xref rid="jah34769-bib-0027" ref-type="ref">27</xref> In their proofâofâconcept study, lowâdose intracoronary thrombolysis (streptokinase, 250 kU; n=51) was infused over 3Â minutes through a guide catheter at the end of primary PCI and, when compared with standard care (n=44), resulted in a significant increase in CFR and decrease in IMR (CFR, 2.5 versus 1.7; <italic>P</italic>&lt;0.001; IMR, 20.2 versus 34.2; <italic>P</italic>&lt;0.001).<xref rid="jah34769-bib-0027" ref-type="ref">27</xref>
</p>
              <p>There are important differences between our study and that of Sezer etÂ al.<xref rid="jah34769-bib-0027" ref-type="ref">27</xref> First, the study by Sezer etÂ al<xref rid="jah34769-bib-0027" ref-type="ref">27</xref> was not double blinded, whereas our study was. Second, streptokinase is not fibrin specific, whereas alteplase is. Third, all of the patients in Sezer etÂ al's study<xref rid="jah34769-bib-0027" ref-type="ref">27</xref> received a bolus of tirofiban glycoprotein IIbIIIa inhibitor therapy at the start of the procedure followed by tirofiban infusion for 12Â hours, whereas only 6% of patients in our study received a glycoprotein IIbIIIa inhibitor, in line with current practice guideline recommendations.<xref rid="jah34769-bib-0028" ref-type="ref">28</xref> Fourth, streptokinase was delivered poststent when 89% of the cohort had TIMI 3 coronary flow, whereas we administered alteplase prestent. In our study, 46 patients (32%) had TIMI coronary flow â¤2 immediately prestudy drug, which may have limited alteplase reaching the downstream microcirculation, and prothrombotic effects of fibrinolytics might be enhanced in conditions of slow flow.<xref rid="jah34769-bib-0029" ref-type="ref">29</xref>, <xref rid="jah34769-bib-0030" ref-type="ref">30</xref> Fifth, we measured coronary physiology immediately after the primary PCI procedure, whereas Sezer etÂ al<xref rid="jah34769-bib-0027" ref-type="ref">27</xref> measured IMR and CFR 48 hours after primary PCI, when IMR and CFR may have undergone partial recovery.<xref rid="jah34769-bib-0031" ref-type="ref">31</xref>, <xref rid="jah34769-bib-0032" ref-type="ref">32</xref>, <xref rid="jah34769-bib-0033" ref-type="ref">33</xref>
</p>
              <p>In exploratory prespecified subgroup analyses, which were intended to provide mechanistic insights and should be interpreted as hypothesis generating, interactions were observed between ischemic time and alteplase with CFR and RRR, but not IMR. The improvement in microvascular vasodilator function with alteplase, as reflected by higher CFR and RRR, in patients with ischemic time &lt;2Â hours may be explained by those patients presenting with a brief ischemic time having intact microcirculation, which was modifiable by therapy, whereas those with a longer ischemic time may have had irreversible microvascular injury. While these observations could be attributed to type 1 statistical error, our findings are supported by consistent effects of ischemic time on extent of microvascular obstruction, for which the <italic>P</italic> value for interaction was significant.</p>
              <p>In our study, alteplase was associated with more microvascular obstruction in patients with an ischemic time â¥4Â hours. The findings suggest the possibility of alteplase having a detrimental effect on myocardial reperfusion in patients with longer ischemic time. The mechanism may involve alteplase promoting myocardial hemorrhage in circumstances of prolonged ischemia, characterized by capillary degradation<xref rid="jah34769-bib-0034" ref-type="ref">34</xref> and myocyte necrosis. An increase in extravasation of blood into the interstitial space of the infarct core results in external compression of capillaries, with an associated increase in microvascular resistance. This leads to more microvascular obstruction and potentiates the progression of myocardial hemorrhage. The findings support the rationale to limit eligibility to a short ischemic time (eg, &lt;4Â hours).</p>
              <p>A plausible explanation for the lack of interaction between ischemic time and alteplase with IMR could be because IMR measures microvascular resistance during maximal hyperemia, which might be less modifiable by intracoronary alteplase than microvascular vasodilator function (measured by RRR and CFR).</p>
              <p>Two other ongoing trials of lowâdose intracoronary fibrinolysis are using IMR as an eligibility criterion and to measure acute microvascular function after intervention. The RESTOREâMI (Restoring Microcirculatory Perfusion in STEMI) trial (ACTRN12618000778280) will randomize STEMI patients with IMR &gt;32 (n=800) to intracoronary tenecteplase (oneâthird of weightâbased systemic dose) or placebo, in a doubleâblind design, and those with IMR â¤32 will continue in a followup registry. Recently, a pilot trial in 36 patients with acute STEMI with symptoms â¤ 6 hours and TIMI 0/1 flow in the culprit artery demonstrated adjunctive lowâdose (4 mg) of intracoronary tenecteplase given twice (postâreperfusion and at the end of PCI, 8 mg total) compared with placebo (saline) as an adjunct to primary PCI was feasible and safe but did not improve percent stenosis of the culprit lesion (primary outcome).<xref rid="jah34769-bib-0035" ref-type="ref">35</xref> The smaller OPTIMAL (Optimal Coronary Flow After PCI for Myocardial Infarction) trial (NCT02894138) will randomize 80 STEMI patients with a poststenting IMR &gt;30 to intracoronary alteplase (20mg), or placebo, in an openâlabel design. Both studies are including patients with ischemic times up to 12Â hours. However, our findings suggest that therapeutic benefit with alteplase might be restricted to patients with a shorter ischemic time.</p>
              <sec id="jah34769-sec-0032">
                <title>Limitations and Strengths</title>
                <p>Because of the potential for type 1 error in the subgroup analyses, these should be interpreted as exploratory. Although we observed a higher TIMI myocardial perfusion grade postâPCI in the alteplase 20Â mg group compared with the placebo group, this difference was not observed in the main trial,<xref rid="jah34769-bib-0009" ref-type="ref">9</xref> and the significant <italic>P</italic> value may have occurred because of chance (type 1 statistical error).</p>
                <p>Strengths of our study include the randomized, doubleâblind design, blinding of IMR, CFR, and RRR measurements to minimize bias, and their excellent interâ and intrarater reliability. Retention with CMR was high (94% at 3Â months).</p>
              </sec>
            </sec>
            <sec id="jah34769-sec-0033">
              <title>Conclusions</title>
              <p>In acute STEMI with ischemic time â¤6Â hours, there was, overall, no difference in culprit artery microvascular function (IMR, CFR, or RRR) at the end of PCI with alteplase versus placebo. Interactions were observed between ischemic time and alteplase on CFR, RRR, and microvascular obstruction, implying therapeutic benefit in patients presenting with a shorter ischemic time and a detrimental effect in patients with a longer ischemic time. Further research seems warranted.</p>
            </sec>
            <sec id="jah34769-sec-0035">
              <title>Sources of Funding</title>
              <p>Dr Maznyczka is funded by a fellowship from the British Heart Foundation (FS/16/74/32573). Dr Berry is supported by grant RE/18/6/34217 from the British Heart Foundation. TâTIME was supported by grant 12/170/4 from the Efficacy and Mechanism Evaluation (EME) program of the National Institute for Health Research (NIHRâEME). Boehringer Ingelheim UK Ltd provided the study drugs (alteplase 10, 20Â mg), matched placebo, and sterile water for injection. These organizations had no other involvement in the conduct of the study or in any aspect of the manuscript.</p>
            </sec>
            <sec id="jah34769-sec-0036">
              <title>Disclosures</title>
              <p>Dr Berry is employed by the University of Glasgow, which holds research and/or consultancy agreements with AstraZeneca, Abbott Vascular, Boehringer Ingelheim, GSK, HeartFlow, Opsens, and Novartis. Dr Oldroyd has received speaker fees and research support from Abbott Vascular and Boston Scientific. Dr Tait reported receiving grants from the National Institute for Health Research (NIHR) during the conduct of the study, consultancy fees and honoraria from Boehringer Ingelheim and Sobi, consultancy fees and nonfinancial support from Bayer Healthcare, NovoNordisk, and Shire, consultancy fees from Pfizer, and nonfinancial support from CSL Behring. Dr Cotton reported research support and speaker fees from Abbott Vascular. Dr Watkins reports speaker fees from Biosensors International, GE Healthcare, Abbott, Sanofi, and AstraZeneca. Welsh reported receiving grants from the Chief Scientist Office, Boehringer Ingelheim, and Roche. Sattar reported receiving grants and personal fees from Boehringer Ingelheim and personal fees from Amgen, Eli Lilly, Janssen, and AstraZeneca outside the submitted work. Dr Robertson reported receiving speaker fees and educational support from AstraZeneca and educational support from Abbott Vascular.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah34769-sup-0001">
                <caption>
                  <p><bold>Data S1.</bold> Eligibility Criteria.</p>
                  <p><bold>TableÂ S1.</bold> CMR End Points</p>
                  <p><bold>TableÂ S2.</bold> Coagulation and Hematological Variables</p>
                  <p><bold>TableÂ S3.</bold> IMR, CFR, and RRR in Subgroups of TIMI Coronary Flow Grade Immediately Before Study Drug Delivery</p>
                  <p><bold>TableÂ S4.</bold> IMR, CFR, and RRR in Subgroups of TIMI Thrombus Grade Immediately Before Study Drug Delivery</p>
                </caption>
                <media xlink:href="JAH3-9-e014066-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah34769-sec-0034">
              <title>Acknowledgments</title>
              <p>We thank the patients who participated in this study and the TâTIME investigators and staff who supported it.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah34769-bibl-0001">
              <title>References</title>
              <ref id="jah34769-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0001"><string-name><surname>Hombach</surname><given-names>V</given-names></string-name>, <string-name><surname>Grebe</surname><given-names>O</given-names></string-name>, <string-name><surname>Merkle</surname><given-names>N</given-names></string-name>, <string-name><surname>Waldenmaier</surname><given-names>S</given-names></string-name>, <string-name><surname>Hoher</surname><given-names>M</given-names></string-name>, <string-name><surname>Kochs</surname><given-names>M</given-names></string-name>, <string-name><surname>Wohrle</surname><given-names>J</given-names></string-name>, <string-name><surname>Kestler</surname><given-names>HA</given-names></string-name>. <article-title>Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2005</year>;<volume>26</volume>:<fpage>549</fpage>â<lpage>557</lpage>.<pub-id pub-id-type="pmid">15713695</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0002"><string-name><surname>de Waha</surname><given-names>S</given-names></string-name>, <string-name><surname>Patel</surname><given-names>MR</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Ohman</surname><given-names>EM</given-names></string-name>, <string-name><surname>Maehara</surname><given-names>A</given-names></string-name>, <string-name><surname>Eitel</surname><given-names>I</given-names></string-name>, <string-name><surname>BenâYehuda</surname><given-names>O</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>P</given-names></string-name>, <string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Stone</surname><given-names>GW</given-names></string-name>. <article-title>Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for STâsegment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2017</year>;<volume>38</volume>:<fpage>3502</fpage>â<lpage>3510</lpage>.<pub-id pub-id-type="pmid">29020248</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0003"><string-name><surname>Carrick</surname><given-names>D</given-names></string-name>, <string-name><surname>Haig</surname><given-names>C</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Petrie</surname><given-names>MC</given-names></string-name>, <string-name><surname>Eteiba</surname><given-names>H</given-names></string-name>, <string-name><surname>Hood</surname><given-names>S</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>S</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>MM</given-names></string-name>, <string-name><surname>Davie</surname><given-names>A</given-names></string-name>, <string-name><surname>Mahrous</surname><given-names>A</given-names></string-name>, <string-name><surname>Mordi</surname><given-names>I</given-names></string-name>, <string-name><surname>Rauhalammi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Welsh</surname><given-names>P</given-names></string-name>, <string-name><surname>Radjenovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>Myocardial hemorrhage after acute reperfused stâsegmentâelevation myocardial infarction: relation to microvascular obstruction and prognostic significance</article-title>. <source xml:lang="en">Circ Cardiovasc Imaging</source>. <year>2016</year>;<volume>9</volume>:<fpage>e004148</fpage>.<pub-id pub-id-type="pmid">26763281</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0004"><string-name><surname>Levine</surname><given-names>GN</given-names></string-name>, <string-name><surname>Bates</surname><given-names>ER</given-names></string-name>, <string-name><surname>Bittl</surname><given-names>JA</given-names></string-name>, <string-name><surname>Brindis</surname><given-names>RG</given-names></string-name>, <string-name><surname>Fihn</surname><given-names>SD</given-names></string-name>, <string-name><surname>Fleisher</surname><given-names>LA</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Lange</surname><given-names>RA</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Mukherjee</surname><given-names>D</given-names></string-name>, <string-name><surname>Newby</surname><given-names>LK</given-names></string-name>, <string-name><surname>O'Gara</surname><given-names>PT</given-names></string-name>, <string-name><surname>Sabatine</surname><given-names>MS</given-names></string-name>, <string-name><surname>Smith</surname><given-names>PK</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>. <article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force On Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the management of STâelevation myocardial infarction, 2014 AHA/ACC Guideline for the management of patients with nonâSTâelevation acute coronary syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery</article-title>. <source xml:lang="en">Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>e123</fpage>â<lpage>e155</lpage>.<pub-id pub-id-type="pmid">27026020</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0005"><string-name><surname>Robbers</surname><given-names>LF</given-names></string-name>, <string-name><surname>Eerenberg</surname><given-names>ES</given-names></string-name>, <string-name><surname>Teunissen</surname><given-names>PF</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>MF</given-names></string-name>, <string-name><surname>Hollander</surname><given-names>MR</given-names></string-name>, <string-name><surname>Horrevoets</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Knaapen</surname><given-names>P</given-names></string-name>, <string-name><surname>Nijveldt</surname><given-names>R</given-names></string-name>, <string-name><surname>Heymans</surname><given-names>NW</given-names></string-name>, <string-name><surname>Levi</surname><given-names>MM</given-names></string-name>, <string-name><surname>van Rossum</surname><given-names>AC</given-names></string-name>, <string-name><surname>Niessen</surname><given-names>HW</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>CB</given-names></string-name>, <string-name><surname>Beek</surname><given-names>AM</given-names></string-name>, <string-name><surname>van Royen</surname><given-names>N</given-names></string-name>. <article-title>Magnetic resonance imagingâdefined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2013</year>;<volume>34</volume>:<fpage>2346</fpage>â<lpage>2353</lpage>.<pub-id pub-id-type="pmid">23594591</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0006"><string-name><surname>Zalewski</surname><given-names>J</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>K</given-names></string-name>, <string-name><surname>Desmet</surname><given-names>W</given-names></string-name>, <string-name><surname>Sinnaeve</surname><given-names>P</given-names></string-name>, <string-name><surname>Berger</surname><given-names>P</given-names></string-name>, <string-name><surname>Grines</surname><given-names>C</given-names></string-name>, <string-name><surname>Danays</surname><given-names>T</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>P</given-names></string-name>, <string-name><surname>Van de Werf</surname><given-names>F</given-names></string-name>. <article-title>Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENTâ4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>1867</fpage>â<lpage>1873</lpage>.<pub-id pub-id-type="pmid">21545942</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0007"><collab collab-type="authors">Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENTâ4 PCI) investigators</collab>
. <article-title>Primary versus tenecteplaseâfacilitated percutaneous coronary intervention in patients with STâsegment elevation acute myocardial infarction (ASSENTâ4 PCI): randomised trial</article-title>. <source xml:lang="en">Lancet</source>. <year>2006</year>;<volume>367</volume>:<fpage>569</fpage>â<lpage>578</lpage>.<pub-id pub-id-type="pmid">16488800</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0008"><string-name><surname>Ellis</surname><given-names>SG</given-names></string-name>, <string-name><surname>Tendera</surname><given-names>M</given-names></string-name>, <string-name><surname>de Belder</surname><given-names>MA</given-names></string-name>, <string-name><surname>van Boven</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Widimsky</surname><given-names>P</given-names></string-name>, <string-name><surname>Janssens</surname><given-names>L</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>HR</given-names></string-name>, <string-name><surname>Betriu</surname><given-names>A</given-names></string-name>, <string-name><surname>Savonitto</surname><given-names>S</given-names></string-name>, <string-name><surname>Adamus</surname><given-names>J</given-names></string-name>, <string-name><surname>Peruga</surname><given-names>JZ</given-names></string-name>, <string-name><surname>Kosmider</surname><given-names>M</given-names></string-name>, <string-name><surname>Katz</surname><given-names>O</given-names></string-name>, <string-name><surname>Neunteufl</surname><given-names>T</given-names></string-name>, <string-name><surname>Jorgova</surname><given-names>J</given-names></string-name>, <string-name><surname>Dorobantu</surname><given-names>M</given-names></string-name>, <string-name><surname>Grinfeld</surname><given-names>L</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>P</given-names></string-name>, <string-name><surname>Brodie</surname><given-names>BR</given-names></string-name>, <string-name><surname>Hermsnn</surname><given-names>HC</given-names></string-name>, <string-name><surname>Montalescot</surname><given-names>G</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name><surname>Barathan</surname><given-names>ES</given-names></string-name>, <string-name><surname>Topol</surname><given-names>EF</given-names></string-name>; <collab collab-type="authors">FINESSE Investigators</collab>
. <article-title>Facilitated PCI in patients with STâelevation myocardial infarction</article-title>. <source xml:lang="en">N Eng J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>2205</fpage>â<lpage>2217</lpage>.</mixed-citation>
              </ref>
              <ref id="jah34769-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0009"><string-name><surname>McCartney</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Eteiba</surname><given-names>H</given-names></string-name>, <string-name><surname>Maznyczka</surname><given-names>AM</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Greenwood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Muir</surname><given-names>DF</given-names></string-name>, <string-name><surname>Chowdhury</surname><given-names>S</given-names></string-name>, <string-name><surname>Gershlick</surname><given-names>AH</given-names></string-name>, <string-name><surname>Appleby</surname><given-names>C</given-names></string-name>, <string-name><surname>Cottin</surname><given-names>JM</given-names></string-name>, <string-name><surname>Wragg</surname><given-names>A</given-names></string-name>, <string-name><surname>Curzen</surname><given-names>N</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>M</given-names></string-name>, <string-name><surname>Rocchiccioli</surname><given-names>JP</given-names></string-name>, <string-name><surname>Shaukat</surname><given-names>A</given-names></string-name>, <string-name><surname>Good</surname><given-names>R</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>S</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>K</given-names></string-name>, <string-name><surname>Malkin</surname><given-names>C</given-names></string-name>, <string-name><surname>Martin</surname><given-names>L</given-names></string-name>, <string-name><surname>Gillespie</surname><given-names>L</given-names></string-name>, <string-name><surname>Ford</surname><given-names>T</given-names></string-name>, <string-name><surname>Petrie</surname><given-names>MC</given-names></string-name>, <string-name><surname>Macfarlane</surname><given-names>PW</given-names></string-name>, <string-name><surname>Tait</surname><given-names>RC</given-names></string-name>, <string-name><surname>Welsh</surname><given-names>P</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Weir</surname><given-names>RA</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>McConnachie</surname><given-names>A</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>Effect of lowâdose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>56</fpage>â<lpage>68</lpage>.<pub-id pub-id-type="pmid">30620371</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0010"><string-name><surname>Maznyczka</surname><given-names>AM</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>, <string-name><surname>McCartney</surname><given-names>P</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>The use of index of microcirculatory resistance (IMR) to guide stratification of patients for adjunctive therapy in acute myocardial infarction</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2019</year>;<volume>12</volume>:<fpage>951</fpage>â<lpage>966</lpage>.<pub-id pub-id-type="pmid">31122353</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0011"><string-name><surname>van Leeuwen</surname><given-names>MAH</given-names></string-name>, <string-name><surname>van der Hoeven</surname><given-names>NW</given-names></string-name>, <string-name><surname>Janssens</surname><given-names>GN</given-names></string-name>, <string-name><surname>Everaars</surname><given-names>H</given-names></string-name>, <string-name><surname>Nap</surname><given-names>A</given-names></string-name>, <string-name><surname>Lemkes</surname><given-names>JS</given-names></string-name>, <string-name><surname>de Waard</surname><given-names>GA</given-names></string-name>, <string-name><surname>van de Ven</surname><given-names>PM</given-names></string-name>, <string-name><surname>van Rossum</surname><given-names>AC</given-names></string-name>, <string-name><surname>Ten Cate</surname><given-names>TJF</given-names></string-name>, <string-name><surname>Piek</surname><given-names>JJ</given-names></string-name>, <string-name><surname>von Birgelen</surname><given-names>C</given-names></string-name>, <string-name><surname>Escaned</surname><given-names>J</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name><surname>Diletti</surname><given-names>R</given-names></string-name>, <string-name><surname>Riksen</surname><given-names>NP</given-names></string-name>, <string-name><surname>van Mieghem</surname><given-names>NM</given-names></string-name>, <string-name><surname>Nijveldt</surname><given-names>R</given-names></string-name>. <article-title>Evaluation of microvascular injury in revascularized patients with STâsegmentâelevation myocardial infarction treated with ticagrelor versus prasugrel</article-title>. <source xml:lang="en">Circulation</source>. <year>2019</year>;<volume>139</volume>:<fpage>636</fpage>â<lpage>646</lpage>.<pub-id pub-id-type="pmid">30586720</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0012"><string-name><surname>Carrick</surname><given-names>D</given-names></string-name>, <string-name><surname>Haig</surname><given-names>C</given-names></string-name>, <string-name><surname>Carberry</surname><given-names>J</given-names></string-name>, <string-name><surname>May</surname><given-names>VTY</given-names></string-name>, <string-name><surname>McCartney</surname><given-names>P</given-names></string-name>, <string-name><surname>Welsh</surname><given-names>P</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Petrie</surname><given-names>MC</given-names></string-name>, <string-name><surname>Eteiba</surname><given-names>H</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>M</given-names></string-name>, <string-name><surname>Hood</surname><given-names>S</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>S</given-names></string-name>, <string-name><surname>Mahrous</surname><given-names>A</given-names></string-name>, <string-name><surname>Rauhalammi</surname><given-names>SM</given-names></string-name>, <string-name><surname>Mordi</surname><given-names>I</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>Radjenovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Sattar</surname><given-names>N</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>Microvascular resistance of the culprit coronary artery in acute STâelevation myocardial infarction</article-title>. <source xml:lang="en">JCI Insight</source>. <year>2016</year>;<volume>1</volume>:<fpage>e85768</fpage>.<pub-id pub-id-type="pmid">27699259</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0013"><string-name><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name><surname>Low</surname><given-names>AF</given-names></string-name>, <string-name><surname>Yong</surname><given-names>AS</given-names></string-name>, <string-name><surname>McGeoch</surname><given-names>R</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>, <string-name><surname>Shah</surname><given-names>MG</given-names></string-name>, <string-name><surname>Ho</surname><given-names>MY</given-names></string-name>, <string-name><surname>Kim</surname><given-names>HS</given-names></string-name>, <string-name><surname>Loh</surname><given-names>JP</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>. <article-title>Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention</article-title>. <source xml:lang="en">Circulation</source>. <year>2013</year>;<volume>127</volume>:<fpage>2436</fpage>â<lpage>2441</lpage>.<pub-id pub-id-type="pmid">23681066</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0014"><string-name><surname>De Maria</surname><given-names>GL</given-names></string-name>, <string-name><surname>Alkhalil</surname><given-names>M</given-names></string-name>, <string-name><surname>Wolfrum</surname><given-names>M</given-names></string-name>, <string-name><surname>Fahrni</surname><given-names>G</given-names></string-name>, <string-name><surname>Borlotti</surname><given-names>A</given-names></string-name>, <string-name><surname>Gaughran</surname><given-names>L</given-names></string-name>, <string-name><surname>Dawkins</surname><given-names>S</given-names></string-name>, <string-name><surname>Langrish</surname><given-names>JP</given-names></string-name>, <string-name><surname>Lucking</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>RP</given-names></string-name>, <string-name><surname>Porto</surname><given-names>I</given-names></string-name>, <string-name><surname>Crea</surname><given-names>F</given-names></string-name>, <string-name><surname>Dall'Armellina</surname><given-names>E</given-names></string-name>, <string-name><surname>Channon</surname><given-names>KM</given-names></string-name>, <string-name><surname>Kharbanda</surname><given-names>RK</given-names></string-name>, <string-name><surname>Banning</surname><given-names>AP</given-names></string-name>. <article-title>Index of microcirculatory resistance as a tool to characterize microvascular obstruction and to predict infarct size regression in patients with stemi undergoing primary PCI</article-title>. <source xml:lang="en">JACC Cardiovasc Imaging</source>. <year>2019</year>;<volume>12</volume>:<fpage>837</fpage>â<lpage>848</lpage>.<pub-id pub-id-type="pmid">29680355</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0015"><string-name><surname>Carrick</surname><given-names>D</given-names></string-name>, <string-name><surname>Haig</surname><given-names>C</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name><surname>Carberry</surname><given-names>J</given-names></string-name>, <string-name><surname>Yue May</surname><given-names>VT</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Petrie</surname><given-names>MC</given-names></string-name>, <string-name><surname>Eteiba</surname><given-names>H</given-names></string-name>, <string-name><surname>Lindsay</surname><given-names>M</given-names></string-name>, <string-name><surname>Hood</surname><given-names>S</given-names></string-name>, <string-name><surname>Watkins</surname><given-names>S</given-names></string-name>, <string-name><surname>Davie</surname><given-names>A</given-names></string-name>, <string-name><surname>Mahrous</surname><given-names>A</given-names></string-name>, <string-name><surname>Mordi</surname><given-names>I</given-names></string-name>, <string-name><surname>Ford</surname><given-names>I</given-names></string-name>, <string-name><surname>Radjenovic</surname><given-names>A</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>KG</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute STâsegmentâelevation myocardial infarction</article-title>. <source xml:lang="en">Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>1833</fpage>â<lpage>1847</lpage>.<pub-id pub-id-type="pmid">27803036</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0016"><string-name><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name><surname>Shah</surname><given-names>M</given-names></string-name>, <string-name><surname>Ng</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>T</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>A</given-names></string-name>, <string-name><surname>Tremmel</surname><given-names>JA</given-names></string-name>, <string-name><surname>Schnittger</surname><given-names>I</given-names></string-name>, <string-name><surname>Lee</surname><given-names>DP</given-names></string-name>, <string-name><surname>Vagelos</surname><given-names>RH</given-names></string-name>, <string-name><surname>Fitzgerald</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Yock</surname><given-names>PG</given-names></string-name>, <string-name><surname>Yeung</surname><given-names>AC</given-names></string-name>. <article-title>Predictive value of the index of microcirculatory resistance in patients with STâsegment elevation myocardial infarction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>:<fpage>560</fpage>â<lpage>565</lpage>.<pub-id pub-id-type="pmid">18237685</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0017"><string-name><surname>Scarsini</surname><given-names>R</given-names></string-name>, <string-name><surname>De Maria</surname><given-names>GL</given-names></string-name>, <string-name><surname>Borlotti</surname><given-names>A</given-names></string-name>, <string-name><surname>Kotronias</surname><given-names>RA</given-names></string-name>, <string-name><surname>Langrish</surname><given-names>JP</given-names></string-name>, <string-name><surname>Lucking</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>RP</given-names></string-name>, <string-name><surname>Ferreira</surname><given-names>VM</given-names></string-name>, <string-name><surname>Ribichini</surname><given-names>F</given-names></string-name>, <string-name><surname>Channon</surname><given-names>KM</given-names></string-name>, <string-name><surname>Kharbanda</surname><given-names>RK</given-names></string-name>, <string-name><surname>Banning</surname><given-names>AP</given-names></string-name>. <article-title>Incremental value of coronary microcirculation resistive reserve ratio in predicting the extent of myocardial infarction in patients with STEMI. Insights from the Oxford Acute Myocardial Infarction (OxAMI) study</article-title>. <source xml:lang="en">Cardiovasc Revasc Med</source>. <year>2019</year>;<volume>S1553â8389</volume>:<fpage>30091</fpage>.</mixed-citation>
              </ref>
              <ref id="jah34769-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0018"><string-name><surname>Van Herck</surname><given-names>PL</given-names></string-name>, <string-name><surname>Paelinck</surname><given-names>BP</given-names></string-name>, <string-name><surname>Haine</surname><given-names>SE</given-names></string-name>, <string-name><surname>Claeys</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Miljoen</surname><given-names>H</given-names></string-name>, <string-name><surname>Bosmans</surname><given-names>JM</given-names></string-name>, <string-name><surname>Parizel</surname><given-names>PM</given-names></string-name>, <string-name><surname>Vrints</surname><given-names>CJ</given-names></string-name>. <article-title>Impaired coronary flow reserve after a recent myocardial infarction: correlation with infarct size and extent of microvascular obstruction</article-title>. <source xml:lang="en">Int J Cardiol</source>. <year>2013</year>;<volume>167</volume>:<fpage>351</fpage>â<lpage>356</lpage>.<pub-id pub-id-type="pmid">22244483</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0019"><collab collab-type="authors">General Assembly of the World Medical Association</collab>
. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source xml:lang="en">JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>2191</fpage>â<lpage>2194</lpage>.<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0020"><string-name><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name><surname>Balsam</surname><given-names>LB</given-names></string-name>, <string-name><surname>Farouque</surname><given-names>HM</given-names></string-name>, <string-name><surname>Caffarelli</surname><given-names>AD</given-names></string-name>, <string-name><surname>Robbins</surname><given-names>RC</given-names></string-name>, <string-name><surname>Fitzgerald</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Yock</surname><given-names>PG</given-names></string-name>, <string-name><surname>Yeung</surname><given-names>AC</given-names></string-name>. <article-title>Novel index for invasively assessing the coronary microcirculation</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>3129</fpage>â<lpage>3132</lpage>.<pub-id pub-id-type="pmid">12821539</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0021"><string-name><surname>Aarnoudse</surname><given-names>W</given-names></string-name>, <string-name><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name><surname>Manoharan</surname><given-names>G</given-names></string-name>, <string-name><surname>Geven</surname><given-names>M</given-names></string-name>, <string-name><surname>van de Vosse</surname><given-names>F</given-names></string-name>, <string-name><surname>Rutten</surname><given-names>M</given-names></string-name>, <string-name><surname>De Bruyne</surname><given-names>B</given-names></string-name>, <string-name><surname>Pijls</surname><given-names>NH</given-names></string-name>. <article-title>Epicardial stenosis severity does not affect minimal microcirculatory resistance</article-title>. <source xml:lang="en">Circulation</source>. <year>2004</year>;<volume>110</volume>:<fpage>2137</fpage>â<lpage>2142</lpage>.<pub-id pub-id-type="pmid">15466646</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0022"><string-name><surname>Yong</surname><given-names>AS</given-names></string-name>, <string-name><surname>Layland</surname><given-names>J</given-names></string-name>, <string-name><surname>Fearon</surname><given-names>WF</given-names></string-name>, <string-name><surname>Ho</surname><given-names>M</given-names></string-name>, <string-name><surname>Shah</surname><given-names>MG</given-names></string-name>, <string-name><surname>Daniels</surname><given-names>D</given-names></string-name>, <string-name><surname>Whitbourn</surname><given-names>R</given-names></string-name>, <string-name><surname>Macisaac</surname><given-names>A</given-names></string-name>, <string-name><surname>Kritharides</surname><given-names>L</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>A</given-names></string-name>, <string-name><surname>Ng</surname><given-names>MK</given-names></string-name>. <article-title>Calculation of the index of microcirculatory resistance without coronary wedge pressure measurement in the presence of epicardial stenosis</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2013</year>;<volume>6</volume>:<fpage>53</fpage>â<lpage>58</lpage>.<pub-id pub-id-type="pmid">23347861</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0023"><string-name><surname>Knaapen</surname><given-names>P</given-names></string-name>, <string-name><surname>Camici</surname><given-names>PG</given-names></string-name>, <string-name><surname>Marques</surname><given-names>KM</given-names></string-name>, <string-name><surname>Nijveldt</surname><given-names>R</given-names></string-name>, <string-name><surname>Bax</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Westerhof</surname><given-names>N</given-names></string-name>, <string-name><surname>Gotte</surname><given-names>MJ</given-names></string-name>, <string-name><surname>JeroschâHerold</surname><given-names>M</given-names></string-name>, <string-name><surname>Schelbert</surname><given-names>HR</given-names></string-name>, <string-name><surname>Lammertsma</surname><given-names>AA</given-names></string-name>, <string-name><surname>van Rossum</surname><given-names>AC</given-names></string-name>. <article-title>Coronary microvascular resistance: methods for its quantification in humans</article-title>. <source xml:lang="en">Basic Res Cardiol</source>. <year>2009</year>;<volume>104</volume>:<fpage>485</fpage>â<lpage>498</lpage>.<pub-id pub-id-type="pmid">19468781</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0024"><string-name><surname>De Bruyne</surname><given-names>B</given-names></string-name>, <string-name><surname>Pijls</surname><given-names>NH</given-names></string-name>, <string-name><surname>Smith</surname><given-names>L</given-names></string-name>, <string-name><surname>Aarnoudse</surname><given-names>W</given-names></string-name>, <string-name><surname>Barbato</surname><given-names>E</given-names></string-name>, <string-name><surname>Bartunek</surname><given-names>J</given-names></string-name>, <string-name><surname>Bech</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Van De Vosse</surname><given-names>F</given-names></string-name>. <article-title>Coronary thermodilution to assess flow reserve: experimental validation</article-title>. <source xml:lang="en">Circulation</source>. <year>2001</year>;<volume>104</volume>:<fpage>2003</fpage>â<lpage>2006</lpage>.<pub-id pub-id-type="pmid">11673336</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0025"><string-name><surname>Layland</surname><given-names>J</given-names></string-name>, <string-name><surname>Carrick</surname><given-names>D</given-names></string-name>, <string-name><surname>McEntegart</surname><given-names>M</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>N</given-names></string-name>, <string-name><surname>Payne</surname><given-names>A</given-names></string-name>, <string-name><surname>McClure</surname><given-names>J</given-names></string-name>, <string-name><surname>Sood</surname><given-names>A</given-names></string-name>, <string-name><surname>McGeoch</surname><given-names>R</given-names></string-name>, <string-name><surname>Maclsaac</surname><given-names>A</given-names></string-name>, <string-name><surname>Whitbourn</surname><given-names>R</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>A</given-names></string-name>, <string-name><surname>Oldroyd</surname><given-names>K</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>. <article-title>Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with nonâSTâsegmentâelevation myocardial infarction</article-title>. <source xml:lang="en">Circ Cardiovasc Interv</source>. <year>2013</year>;<volume>6</volume>:<fpage>231</fpage>â<lpage>236</lpage>.<pub-id pub-id-type="pmid">23756697</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0026"><string-name><surname>Fukunaga</surname><given-names>M</given-names></string-name>, <string-name><surname>Fujii</surname><given-names>K</given-names></string-name>, <string-name><surname>Kawasaki</surname><given-names>D</given-names></string-name>, <string-name><surname>Sawada</surname><given-names>H</given-names></string-name>, <string-name><surname>Miki</surname><given-names>K</given-names></string-name>, <string-name><surname>Tamaru</surname><given-names>H</given-names></string-name>, <string-name><surname>Imanaka</surname><given-names>T</given-names></string-name>, <string-name><surname>Iwasaku</surname><given-names>T</given-names></string-name>, <string-name><surname>Nakata</surname><given-names>T</given-names></string-name>, <string-name><surname>Chibuya</surname><given-names>M</given-names></string-name>, <string-name><surname>Akahori</surname><given-names>H</given-names></string-name>, <string-name><surname>Masutani</surname><given-names>M</given-names></string-name>, <string-name><surname>Kobayashi</surname><given-names>K</given-names></string-name>, <string-name><surname>Ohyanagi</surname><given-names>M</given-names></string-name>, <string-name><surname>Masuyama</surname><given-names>T</given-names></string-name>. <article-title>Thermodilutionâderived coronary blood flow pattern immediately after coronary intervention as a predictor of microcirculatory damage and midterm clinical outcomes in patients with STâsegmentâelevation myocardial infarction</article-title>. <source xml:lang="en">Circ Cardiovasc Interv</source>. <year>2014</year>;<volume>7</volume>:<fpage>149</fpage>â<lpage>155</lpage>.<pub-id pub-id-type="pmid">24550440</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0027"><string-name><surname>Sezer</surname><given-names>M</given-names></string-name>, <string-name><surname>Cimen</surname><given-names>A</given-names></string-name>, <string-name><surname>Aslanger</surname><given-names>E</given-names></string-name>, <string-name><surname>Elitok</surname><given-names>A</given-names></string-name>, <string-name><surname>Umman</surname><given-names>B</given-names></string-name>, <string-name><surname>Burga</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yormaz</surname><given-names>E</given-names></string-name>, <string-name><surname>Turkmen</surname><given-names>C</given-names></string-name>, <string-name><surname>Adalet</surname><given-names>IS</given-names></string-name>, <string-name><surname>Nisanci</surname><given-names>Y</given-names></string-name>, <string-name><surname>Umman</surname><given-names>S</given-names></string-name>. <article-title>Effect of intracoronary streptokinase administered immediately after primary percutaneous coronary intervention on longâterm left ventricular infarct size, volumes, and function</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>:<fpage>1065</fpage>â<lpage>1071</lpage>.<pub-id pub-id-type="pmid">19744615</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0028"><string-name><surname>O'Gara</surname><given-names>PT</given-names></string-name>, <string-name><surname>Kushner</surname><given-names>FG</given-names></string-name>, <string-name><surname>Ascheim</surname><given-names>DD</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Chung</surname><given-names>MK</given-names></string-name>, <string-name><surname>de Lemos</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ettinger</surname><given-names>SM</given-names></string-name>, <string-name><surname>Fang</surname><given-names>JC</given-names></string-name>, <string-name><surname>Fesmire</surname><given-names>FM</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>BA</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>, <string-name><surname>Linderbaum</surname><given-names>JA</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>DA</given-names></string-name>, <string-name><surname>Newby</surname><given-names>LK</given-names></string-name>, <string-name><surname>Ornato</surname><given-names>JP</given-names></string-name>, <string-name><surname>Ou</surname><given-names>N</given-names></string-name>, <string-name><surname>Radford</surname><given-names>MJ</given-names></string-name>, <string-name><surname>TamisâHolland</surname><given-names>JE</given-names></string-name>, <string-name><surname>Tomasso</surname><given-names>CL</given-names></string-name>, <string-name><surname>Tracy</surname><given-names>CM</given-names></string-name>, <string-name><surname>Woo</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>DX</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>JL</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>AK</given-names></string-name>, <string-name><surname>Halperin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Albert</surname><given-names>NM</given-names></string-name>, <string-name><surname>Brindis</surname><given-names>RG</given-names></string-name>, <string-name><surname>Creager</surname><given-names>MA</given-names></string-name>, <string-name><surname>DeMets</surname><given-names>D</given-names></string-name>, <string-name><surname>Guyton</surname><given-names>RA</given-names></string-name>, <string-name><surname>Hochman</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kovacs</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Kushner</surname><given-names>FG</given-names></string-name>, <string-name><surname>Ohman</surname><given-names>EM</given-names></string-name>, <string-name><surname>Stevenson</surname><given-names>WG</given-names></string-name>, <string-name><surname>Yancy</surname><given-names>CW</given-names></string-name>; <collab collab-type="authors">American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
. <article-title>2013 ACCF/AHA guideline for the management of STâelevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source xml:lang="en">Circulation</source>. <year>2013</year>;<volume>127</volume>:<fpage>e362</fpage>â<lpage>e425</lpage>.<pub-id pub-id-type="pmid">23247304</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0029"><string-name><surname>Berry</surname><given-names>C</given-names></string-name>, <string-name><surname>Maznyczka</surname><given-names>AM</given-names></string-name>, <string-name><surname>McCartney</surname><given-names>P</given-names></string-name>. <article-title>Failed myocardial reperfusion during primary PCI: an unmet therapeutic need</article-title>. <source xml:lang="en">EuroIntervention</source>. <year>2019</year>;<volume>14</volume>:<fpage>1628</fpage>â<lpage>1630</lpage>.<pub-id pub-id-type="pmid">30956186</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0030"><string-name><surname>MoralesâPonce</surname><given-names>FJ</given-names></string-name>, <string-name><surname>LozanoâCid</surname><given-names>FJ</given-names></string-name>, <string-name><surname>MartinezâRomero</surname><given-names>P</given-names></string-name>, <string-name><surname>GonzalezâPerez</surname><given-names>P</given-names></string-name>, <string-name><surname>SanchezâBrotons</surname><given-names>JA</given-names></string-name>, <string-name><surname>DiazâTorres</surname><given-names>I</given-names></string-name>, <string-name><surname>RodriguezâYanez</surname><given-names>JC</given-names></string-name>, <string-name><surname>CaroâMateo</surname><given-names>P</given-names></string-name>, <string-name><surname>SerradorâFrutos</surname><given-names>AM</given-names></string-name>. <article-title>Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction</article-title>. <source xml:lang="en">EuroIntervention</source>. <year>2019</year>;<volume>14</volume>:<fpage>1668</fpage>â<lpage>1675</lpage>.<pub-id pub-id-type="pmid">30418157</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0031"><string-name><surname>Cuculi</surname><given-names>F</given-names></string-name>, <string-name><surname>Dall'Armellina</surname><given-names>E</given-names></string-name>, <string-name><surname>Manlhiot</surname><given-names>C</given-names></string-name>, <string-name><surname>De Caterina</surname><given-names>AR</given-names></string-name>, <string-name><surname>Colyer</surname><given-names>S</given-names></string-name>, <string-name><surname>Ferreira</surname><given-names>V</given-names></string-name>, <string-name><surname>Morovat</surname><given-names>A</given-names></string-name>, <string-name><surname>Prendergast</surname><given-names>BD</given-names></string-name>, <string-name><surname>Forfar</surname><given-names>JC</given-names></string-name>, <string-name><surname>Alp</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>RP</given-names></string-name>, <string-name><surname>Neuauer</surname><given-names>S</given-names></string-name>, <string-name><surname>Channon</surname><given-names>KM</given-names></string-name>, <string-name><surname>Banning</surname><given-names>AP</given-names></string-name>, <string-name><surname>Kharbanda</surname><given-names>RK</given-names></string-name>. <article-title>Early change in invasive measures of microvascular function can predict myocardial recovery following PCI for STâelevation myocardial infarction</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2014</year>;<volume>35</volume>:<fpage>1971</fpage>â<lpage>1980</lpage>.<pub-id pub-id-type="pmid">24135835</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0032"><string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Kosa</surname><given-names>I</given-names></string-name>, <string-name><surname>Dickfeld</surname><given-names>T</given-names></string-name>, <string-name><surname>Blasini</surname><given-names>R</given-names></string-name>, <string-name><surname>Gawaz</surname><given-names>M</given-names></string-name>, <string-name><surname>Hausleiter</surname><given-names>J</given-names></string-name>, <string-name><surname>Schwaiger</surname><given-names>M</given-names></string-name>, <string-name><surname>Schomig</surname><given-names>A</given-names></string-name>. <article-title>Recovery of myocardial perfusion in acute myocardial infarction after successful balloon angioplasty and stent placement in the infarctârelated coronary artery</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>1997</year>;<volume>30</volume>:<fpage>1270</fpage>â<lpage>1276</lpage>.<pub-id pub-id-type="pmid">9350926</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0033"><string-name><surname>Cuculi</surname><given-names>F</given-names></string-name>, <string-name><surname>De Maria</surname><given-names>GL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>P</given-names></string-name>, <string-name><surname>Dall'Armerllina</surname><given-names>E</given-names></string-name>, <string-name><surname>de Caterina</surname><given-names>AR</given-names></string-name>, <string-name><surname>Channon</surname><given-names>KM</given-names></string-name>, <string-name><surname>Prendergast</surname><given-names>BD</given-names></string-name>, <string-name><surname>Choudhury</surname><given-names>RP</given-names></string-name>, <string-name><surname>Forfar</surname><given-names>JC</given-names></string-name>, <string-name><surname>Kharbanda</surname><given-names>RK</given-names></string-name>, <string-name><surname>Banning</surname><given-names>AP</given-names></string-name>. <article-title>Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after STâsegment elevation myocardial infarction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>1894</fpage>â<lpage>1904</lpage>.<pub-id pub-id-type="pmid">25444143</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0034"><string-name><surname>Galaup</surname><given-names>A</given-names></string-name>, <string-name><surname>Gomez</surname><given-names>E</given-names></string-name>, <string-name><surname>Souktani</surname><given-names>R</given-names></string-name>, <string-name><surname>Durand</surname><given-names>M</given-names></string-name>, <string-name><surname>Cazes</surname><given-names>A</given-names></string-name>, <string-name><surname>Monnot</surname><given-names>C</given-names></string-name>, <string-name><surname>Teillon</surname><given-names>J</given-names></string-name>, <string-name><surname>Le Jan</surname><given-names>S</given-names></string-name>, <string-name><surname>Bouleti</surname><given-names>C</given-names></string-name>, <string-name><surname>Briois</surname><given-names>G</given-names></string-name>, <string-name><surname>Philippe</surname><given-names>J</given-names></string-name>, <string-name><surname>Pons</surname><given-names>S</given-names></string-name>, <string-name><surname>Martin</surname><given-names>V</given-names></string-name>, <string-name><surname>Assaly</surname><given-names>R</given-names></string-name>, <string-name><surname>Bonnin</surname><given-names>P</given-names></string-name>, <string-name><surname>Ratajczak</surname><given-names>P</given-names></string-name>, <string-name><surname>Janin</surname><given-names>A</given-names></string-name>, <string-name><surname>Thurston</surname><given-names>G</given-names></string-name>, <string-name><surname>Valenzuela</surname><given-names>DM</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Yancopoulos</surname><given-names>GD</given-names></string-name>, <string-name><surname>Tissier</surname><given-names>R</given-names></string-name>, <string-name><surname>Berdeaux</surname><given-names>A</given-names></string-name>, <string-name><surname>Ghaleh</surname><given-names>B</given-names></string-name>, <string-name><surname>Germain</surname><given-names>S</given-names></string-name>. <article-title>Protection against myocardial infarction and noâreflow through preservation of vascular integrity by angiopoietinâlike 4</article-title>. <source xml:lang="en">Circulation</source>. <year>2012</year>;<volume>125</volume>:<fpage>140</fpage>â<lpage>149</lpage>.<pub-id pub-id-type="pmid">22086875</pub-id></mixed-citation>
              </ref>
              <ref id="jah34769-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah34769-cit-0035"><string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name><surname>Gopalakrishnan</surname><given-names>L</given-names></string-name>, <string-name><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name><surname>Kazziha</surname><given-names>S</given-names></string-name>, <string-name><surname>Devireddy</surname><given-names>C</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>D</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Stouffer</surname><given-names>GA</given-names></string-name>, <string-name><surname>Mavromatis</surname><given-names>K</given-names></string-name>, <string-name><surname>Grip</surname><given-names>L</given-names></string-name>, <string-name><surname>Bainey</surname><given-names>KR</given-names></string-name><collab collab-type="authors">for the TIMI &amp; PERFUSE Study Group</collab>
. <article-title>Feasibility and Safety of LowâDose IntraâCoronary Tenecteplase During Primary Percutaneous Coronary Intervention for STâElevation Myocardial Infarction (ICE TâTIMI 49)</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2019</year>; DOI: <pub-id pub-id-type="doi">10.1016/j.amjcard.2019.11.018</pub-id>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
